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ABSTRACT 
 
     Cinnamon is used in many countries for treatment of bacterial and 
fungal diseases, cold influenza and as antioxidant agent .Recently, people 
discovered that Cinnamomum cassia induce hypoglycemia and improving 
lipid metabolism in patient with type 2 diabetes mellitus. This study 
tested the antidiabetic and hypoglycemic effect of the Cinnamomum 
verum which available in Sudan. The effect of the plant on the plasma 
glucose, total protein, albumin, bilrubin, cholestrol, low density 
lipoprotein- cholestrol, high density lipoprotein- cholestrol, triglyceride 
and liver enzymes (alanine amino transferase and aspartate amino 
transferase) were evaluated in diabetic and normal rats.                                        
Wistar albino rats were used in the present work .The diabetes was 
induced by injection of alloxan monohydrate at dose of 150 mg/kg body 
weight. The experiment extended over three weeks. Rats were divided into 
four groups each group consisted of 5 rats: GroupA was control group and 
contained normal rats, Group B contained normal rats given orally 
Cinnamon bark powder suspended in distilled water at dose of 1g/ kg body 
weight for 21 days, Group C contained diabetic rats and GroupD contained 
diabetic rats given orally Cinnamon bark powder mixed with distilled 
water at dose of 1g/ kg body weight for 21 days to examine the C. verum 
effect on diabetic rats. The plasma glucose level of all rats were measured 
on day zero and day 3 after overnight fasting to estimate blood glucose 
level for checking whether the diabetes was induced by alloxan injection 
or not.    On day 21st blood was collected from each rats after fasting for 18 
hours to determine the level of plasma glucose at 0 h, then rats were 
injected with 50% glucose at dose of 2g /kg body weight and blood was 
collected to monitor plasma glucose level at 1 h and 2 h after glucose was 
given. On day 22nd rats were sacrificed and the blood was collected to 
 xii
estimate the biochemical parameters. 
  Glucose tolerance test carried out in this experiment showed that, daily 
oral administration of C. verum for 21 days lowered significantly(P≤0.05) 
the plasma glucose level of diabetic rats at 0, 1and 2 h after overnight 
fasting compared to diabetic rat’s not given C. verum. Also at 0 , 1 , 2h 
after overnight fasting, it was noticed that there was no significant 
difference in glucose level between normal control rats and normal rats 
given orally C. verum. The oral administration of C. verum had no 
significant effect on plasma bilrubin, albumin, low density lipoprotein - 
cholestrol, alanine amino transferase concentration and body weight in 
both normal and diabetic rats. Also it was noticed that the oral 
administration of C. verum decreased significantly plasma cholestrol, 
high density lipoprotein-cholestrol, and total protein in diabetic rats when 
compared to normal control rats. But it decreased numerically plasma 
triglyceride in diabetic rats when compared to normal control rats and 
increased numerically plasma AST in diabetic rats when compared to 
normal control rats. 
  This experiment   showed     that    C. verum could be used to lower 
hyperglycemia in type1 diabetic patients, and it is   promising antidiabetic 
agent. 
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  اﻟﻤﺴﺘﺨﻠﺺ 
 
ﻧﺒﺎت اﻟﻘﺮﻓﻪ ﻳﺴﺘﺨﺪم ﻓﻰ آﺜﻴﺮ ﻣﻦ دول اﻟﻌﺎﻟﻢ ﻟﻌﻼج آﺜﻴﺮ ﻣﻦ اﻣﺮاض اﻟﺠﻬﺎز ﺑﺎﻻﺻﺎﺑﺎت       
اﻟﺒﻜﺘﻴﺮﻳﻪ واﻟﻔﻄﺮﻳﻪ آﻤﺎ ﻳﻌﺎﻟﺞ ﻧﺰﻻت اﻟﺒﺮد وﻗﺪ اﺛﺒﺖ ﻓﻌﺎﻟﻴﺘﻪ آﻤﻀﺎد ﻟﻼآﺴﺪﻩ واﺧﻴﺮا اﺛﺒﺘﺖ 
ﻓﻰ هﺬﻩ . ﻣﻦ اﻟﻨﻮع اﻟﺜﺎﻧﻰ اﻟﺪهﻮن  ﻟﻤﺮض اﻟﺴﻜﺮى  ﻻﻳﺾاﻟﻬﻀﻤﻰ ﻓﻌﺎﻟﻴﺘﻪ آﻌﻼج وﻣﺤﺴﻦ 
اﻻﻃﺮوﺣﻪ ﺗﻢ دراﺳﺔ اﻻﺛﺮ اﻟﺨﺎﻓﺾ ﻟﺘﺮآﻴﺰ اﻟﺠﻠﻜﻮز ﻓﻰ اﻟﺪم واﻻﺛﺮ اﻟﻤﻌﺎﻟﺞ ﻟﻤﺮض اﻟﺴﻜﺮى 
اﻟﺒﺮوﺗﻴﻨﺎت ،ﺑﻮاﺳﻄﺔ ﻧﺒﺎت اﻟﻘﺮﻓﻪ ﻣﻦ اﻟﻨﻮع اﻟﻤﺘﻮﻓﺮ ﻓﻰ اﻟﺴﻮدان واﺛﺮ اﻟﻨﺒﺎت ﻋﻠﻰ ﺗﺮآﻴﺰ اﻟﺠﻠﻜﻮز 
 ،آﻠﻮﻳﺴﺘﺮول - ﻣﻨﺨﻔﻀﺔ اﻟﻜﺜﺎﻓﻪ اﻟﻠﻴﺒﻮﺑﺮوﺗﻴﻨﺎت، اﻟﻜﻠﻮﻳﺴﺘﺮول، اﻟﺒﻠﻴﺮوﺑﻴﻦ ، اﻻﻟﺒﻴﻮﻣﻴﻦ، اﻟﻜﻠﻴﻪ 
اﻻﻟﻨﻴﻦ اﻣﻴﻨﻮ ﺗﺮاﻧﺴﻔﻴﺮﻳﺰ )اﻟﺘﺮاﻳﺠﻠﺴﺮﻳﺪات واﻻﻧﺰﻳﻤﻴﻦ ، آﻠﻮﻳﺴﺘﺮول -اﻟﻠﻴﺒﻮﺑﺮوﺗﻴﻨﺎت ﻋﺎﻟﻴﺔ اﻟﻜﺜﺎﻓﻪ
           (.                                                                    اﻣﻴﻨﻮ ﺗﺮاﻧﺴﻔﻴﺮﻳﺰ  و اﻻﺳﺒﺮﺗﻴﺖ
ﻟﺒﺤﺚ ﻋﻠﻰ اﻟﺬآﻮر واﻻﻧﺎث ﻣﻦ ﺟﺮزان وﺳﺘﺮ اﻟﺒﻴﻀﺎء واﻟﺘﻰ ﺗﻢ    اﺟﺮﻳﺖ اﻟﺘﺠﺎرب ﻓﻰ هﺬا ا    
آﻴﻠﻮﺟﺮام ﻣﻦ وزن / ﻣﻞ ﺟﺮام051اﻣﺮاض ﺑﻌﺾ ﻣﻨﻬﺎ ﻋﻦ ﻃﺮﻳﻖ ﺣﻘﻨﻬﺎ ﺑﻤﺎدة اﻻوآﺴﺎن ﺑﺠﺮﻋﺔ 
اﻟﺠﺴﻢ  واﺳﺘﻤﺮت اﻟﺘﺠﺮﺑﻪ ﻟﻤﺪة ﺛﻼﺛﺔ اﺳﺎﺑﻴﻊ ﻣﺘﺼﻠﻪ وﻗﺴﻤﺖ اﻟﺠﺮزان اﻟﻰ ارﺑﻊ ﻣﺠﻤﻮﻋﺎت آﻞ 
، ﻟﻰ ﻣﺠﻤﻮﻋﺔ ﺿﺒﻂ وﻣﺮاﻗﺒﺔ ﻟﻠﺠﺮزان اﻟﺴﻠﻴﻤﻪ اﻟﻤﺠﻤﻮﻋﺔ اﻻو. ﺟﺮزان  5ﻣﺠﻤﻮﻋﻪ ﺗﺘﻜﻮن ﻣﻦ 
اﻟﻘﺮﻓﻪ اﻟﻤﺬاﺑﻪ ﻓﻰ ﻣﺎء ﻣﻘﻄﺮ  ﺑﻤﺴﺤﻮق اﻟﺠﺮزان اﻟﺴﻠﻴﻤﻪ و اﻟﺘﻰ ﺗﻢ ﺗﺠﺮﻳﻌﻬﺎ ﻣﻦ اﻟﻤﺠﻤﻮﻋﺔ اﻟﺜﺎﻧﻴﺔ
اﻟﻤﺠﻤﻮﻋﺔ اﻟﺜﺎﻟﺜﺔ ﻣﻦ اﻟﺠﺮزان اﻟﺘﻰ ﺗﻢ ،ﻳﻮم  12ﻟﻤﺪة   آﻴﻠﻮﺟﺮام ﻣﻦ وزن اﻟﺤﻴﻮان/ﺟﺮام1ﺑﻤﻘﺪار 
ﺑﻤﺎدة اﻻوآﺴﺎن  اﻣﺮاﺿﻬﺎ ﺑﺪاء اﻟﺴﻜﺮى ﺑﻤﺎدة اﻻوآﺴﺎن اﻣﺎ اﻟﻤﺠﻤﻮﻋﺔ اﻟﺮاﺑﻌﺔ واﻟﺘﻰ ﺗﻢ اﻣﺮاﺿﻬﺎ
آﻴﻠﻮﺟﺮام ﻣﻦ وزن /ﺟﺮام1اﻟﻘﺮﻓﻪ اﻟﻤﺬاﺑﻪ ﻓﻰ ﻣﺎء ﻣﻘﻄﺮ ﺑﻤﻘﺪار  اﻳﻀﺎ وﺗﻢ ﺗﺠﺮﻳﻌﻬﺎ ﺑﻤﺴﺤﻮق
ﺗﻢ ﻗﻴﺎس ﺗﺮآﻴﺰ .ﺠﺮزان اﻟﻤﺼﺎﺑﻪ ﺑﻤﺮض اﻟﺴﻜﺮى ﻳﻮم ﻻﺧﺘﺒﺎر اﺛﺮهﺎ ﻓﻰ اﻟ 12ﻟﻤﺪة  اﻟﺤﻴﻮان
ﺳﺎﻋﻪ ﻻﺧﺘﺒﺎر  81اﻟﺠﻠﻜﻮز ﻟﻜﻞ اﻟﻔﺌﺮان ﻓﻰ اﻟﻴﻮم اﻻول و اﻟﺜﺎﻟﺚ ﺑﻌﺪ اﺧﻀﺎﻋﻬﺎ ﻟﻠﺼﻴﺎم ﻟﻤﺪة 
اﺧﺬت ﻋﻴﻨﺎت اﻟﺪم  12ﻓﻰ اﻟﻴﻮم .اﺳﺘﺤﺪاث ﻣﺮض اﻟﺴﻜﺮى    ﻟﻠﻔﺌﺮان اﻟﺘﻰ ﺗﻢ ﺣﻘﻨﻬﺎ ﺑﻤﺎدة اﻻوآﺴﺎن
ﺴﺘﻮى اﻟﺠﻠﻜﻮزﻓﻴﻬﺎ ﻗﺒﻞ ﺣﻘﻦ اﻟﻔﺌﺮان ﺑﻤﺎدة ﻣﻦ آﻞ اﻟﻔﺌﺮان   ﺑﻌﺪ اﺧﻀﺎﻋﻬﺎ ﻟﻠﺼﻴﺎم ﺗﻢ ﻗﻴﺎس ﻣ
آﻴﻠﻮﺟﺮام ﻣﻦ وزن اﻟﺠﺴﻢ ﻓﻰ        /ﺟﺮام 2ﺑﻤﻘﺪار % 05اﻟﺠﻠﻜﻮز ﻣﺒﺎﺷﺮﻩ  ﺛﻢ ﺑﻌﺪ ﺣﻘﻦ اﻟﺠﻠﻜﻮز 
ﺑﻌﺪ ذﺑﺢ اﻟﻔﺌﺮان اﺧﺬت ﻋﻴﻨﺎت اﻟﺪم  22ﻓﻰ اﻟﻴﻮم ،اﻟﺴﺎﻋﺎت اﻻوﻟﻰ و اﻟﺜﺎﻧﻴﻪ ﻟﺘﺤﺪﻳﺪ ﺗﺮآﻴﺰ اﻟﺠﻠﻜﻮز 
                                                                   .     ﻟﻘﻴﺎس ﻣﻮاد آﻴﻤﻮﺣﻴﻮﻳﻪ ﻓﻰ ﺑﻼزﻣﺎ اﻟﺪم
 12اﻇﻬﺮ اﺧﺘﺒﺎر ﺣﺴﺎﺳﻴﺔ اﻟﺠﻠﻜﻮز ﻓﻰ هﺬﻩ اﻟﺘﺠﺮﺑﻪ ان اﻋﻄﺎء ﺟﺮﻋﻪ ﻣﻦ اﻟﻘﺮﻓﺔ ﻳﻮﻣﻴﺎ ﻟﻤﺪة      
ﻳﻮم ادى اﻟﻰ اﻧﺨﻔﺎض ﻣﺴﺘﻮى اﻟﺠﻠﻜﻮز ﻓﻰ ﺑﻼزﻣﺎ اﻟﺪم ﻟﻠﺠﺮزان اﻟﻤﻤﺮﺿﻪ ﺑﺎﻟﺴﻜﺮى ﻓﻰ اﻟﺴﺎﻋﺎت 
اﻳﻀﺎ ﻟﻮﺣﻆ ان ﻓﻰ .  ﺮزان اﻟﻤﻤﺮﺿﻪ  واﻟﺘﻰ ﻟﻢ ﻳﺘﻢ ﺗﺠﺮﻳﻌﻬﺎ ﺑﺎﻟﻘﺮﻓﻪﻣﻘﺎرﻧﺔ ﺑﺎﻟﺠ 2و  1،  0
ﻟﻢ ﺗﺘﺴﺒﺐ اﻟﻘﺮﻓﺔ ﻓﻰ اى ﺗﻐﻴﺮ ﻟﻤﺴﺘﻮى ﺗﺮآﻴﺰ اﻟﺠﻠﻜﻮز ﺑﻴﻦ ﻣﺠﻤﻮﻋﺔ اﻟﻀﺒﻂ  2، 1، 0اﻟﺴﺎﻋﺎت  
vix 
ﻟﻢ ﺗﺘﺴﺒﺐ اﻟﻘﺮﻓﺔ ﻓﻰ اى ﺗﻐﻴﺮ ﻟﻤﺴﺘﻮى ﺗﺮآﻴﺰ . واﻟﺠﺮزان اﻟﺴﻠﻴﻤﻪ اﻟﺘﻰ ﺗﻢ ﺗﺠﺮﻳﻌﻬﺎ ﺑﻤﺴﺤﻮق اﻟﻘﺮﻓﻪ
آﻠﻮﻳﺴﺘﺮول وﻓﻰ  -ﻻﻟﻨﻴﻦ اﻣﻴﻨﻮ ﺗﺮاﻧﺴﻔﻴﺮﻳﺰواﻟﻠﻴﺒﻮﺑﺮوﺗﻴﻦ ﻣﻨﺨﻔﺾ اﻟﻜﺜﺎﻓﻪا،اﻟﺒﻠﻴﺮوﺑﻴﻦ، اﻻﻟﺒﻴﻮﻣﻴﻦ 
واﻳﻀﺎ ﻟﻮﺣﻆ ان ﺗﺠﺮﻳﻊ اﻟﻘﺮﻓﺔ ادى اﻟﻰ . وزن اﻟﺠﺴﻢ  ﻟﻠﺠﺮزان اﻟﻤﻤﺮﺿﻪ ﺑﺎﻟﺴﻜﺮى و اﻟﺴﻠﻴﻤﺔ   
 آﻠﻮﻳﺴﺘﺮول و اﻟﺒﺮوﺗﻴﻨﺎت اﻟﻜﻠﻴﺔ-اﻟﻠﻴﺒﻮﺑﺮوﺗﻴﻨﺎت ﻋﺎﻟﻴﻪ اﻟﻜﺜﺎﻓﻪ، اﻧﺨﻔﺎض ﻓﻰ ﺗﺮآﻴﺰ اﻟﻜﻠﻮﻳﺴﺘﺮول 
اﻟﻘﺮﻓﻪ ادى اﻟﻰ اﻧﺨﻔﺎض  وﻟﻜﻦ ﺗﺠﺮﻳﻊ.ﺎﻟﺴﻜﺮى ﻣﻘﺎرﻧﺔ ﺑﻤﺠﻤﻮﻋﺔ اﻟﻀﺒﻂﻟﻠﺠﺮزان اﻟﻤﻤﺮﺿﻪ ﺑ
ﻟﻠﺠﺮزان اﻟﻤﻤﺮﺿﻪ ﺑﺎﻟﺴﻜﺮى ﻣﻘﺎرﻧﺔ ﺑﻤﺠﻤﻮﻋﺔ اﻟﻀﺒﻂ و  ﻋﺪدﻳﺎ ﻓﻰ  ﺗﺮآﻴﺰ اﻟﺘﺮاﻳﺠﻠﺴﺮﻳﺪات
ارﺗﻔﺎع ﻋﺪدﻳﺎ ﻓﻰ ﺗﺮآﻴﺰ اﻻﺳﺒﺮﺗﻴﺖ اﻣﻴﻨﻮ ﺗﺮاﻧﺴﻔﻴﺮﻳﺰ ﻟﻠﺠﺮزان اﻟﻤﻤﺮﺿﻪ ﺑﺎﻟﺴﻜﺮى ﻣﻘﺎرﻧﺔ 
                                                                         .                       ﺑﻤﺠﻤﻮﻋﺔ اﻟﻀﺒﻂ
وهﻜﺬا ﻳﻤﻜﻦ اﻟﻘﻮل ﺑﺎن اﻟﻘﺮﻓﻪ ﻣﻦ اﻟﻨﻮع اﻟﻤﺘﻮﻓﺮ ﻓﻰ اﻻﺳﻮاق اﻟﺴﻮداﻧﻴﻪ ﻳﻤﻜﻦ اﺳﺘﻌﻤﺎﻟﻬﺎ ﻟﺨﻔﺾ     
. ﻣﺴﺘﻮى اﻟﺠﻠﻜﻮز ﻓﻰ ﻣﺮض اﻟﺴﻜﺮى ﻣﻦ اﻟﻨﻮع اﻻول وهﻰ ﻋﻨﺼﺮ واﻋﺪ ﻟﻤﻌﺎﻟﺠﺔ ﻣﺮض اﻟﺴﻜﺮى
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INTRODUCTION 
People has known the use of medicinal plants since ancient times. 
These plants have been used for the treatment of various disease world wide, 
because of ready availability, their low cost of production and less toxic 
action compared to those of synthetic compounds (Asima and Pakrashi, 
1995). 
In developing countries, like Sudan, where people live in communities 
far away from each other, the inhabitants used to be short of or almost 
deprived of proper medical care. 
Some studies revealed valuable therapeutic activities and pharmacological 
nature as well as nutritional value of herbs. Some spices have an additional 
benefit of having role in carbohydrate metabolism (khan etal, 1990). 
Marles and Farnsworth ( 1994) have reported that one- to two- thirds 
of the 1123 plants that affect blood glucose may be dangerous, and many of 
the phytochemicals are hypoglycemic due to metabolic or hepatic toxicity. 
However, medicinal plants have been used for diabetes safely and with 
reasonable success (Marles and Farnsworth, 1994; Duke etal., 
1998).Botanical product can improve glucose metabolism and overall 
condition of person with diabetes not only by hypoglycemic effect but also 
by improving lipid metabolism and antioxidant status (Broadhurst ,1997) . A 
number of medical herbs have been reported to yield hypoglycemic effect in 
subjects with diabetes .These include cinnamon,clover ,bay leaves ,turmeric 
(Khan etal.,1990  ) ,   Lupinus termis L., Solenostemma argel  (Del) and 
Cicer arietinum ( El Ghazali  etal.,1998) .A study was carried out to 
examine the effect of Cinnamomum cassia powder on type 2 diabetes 
mellitus. The result of the study showed significant decreasing in blood 
glucose of people with type 2 diabetes (Khan etal., 2003).                                       
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This investigation was carried out to evaluate the folkloric uses of C.verum 
for the treatment of diabetes mellitus and was intended to study the effect 
oral administration of Cinnamomum verum bark powder, on diabetic and 
normal rats. 
Objective:-  
  This study aimed: 
‐ To evaluate the hypoglycemic effect of C. verum on normal rats.  
‐ To evaluate the hypoglycemic and antidiabetic effect of C. verum on 
alloxan induced diabetic rats. 
‐ To examine for the toxicity of the C. verum.  
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CHAPTER ONE 
LITERATURE REVIEW 
 1.1     Pancreas: 
1.1.1 The anatomy of pancreas: 
The pancreas is an elongated organ, light tan or pinkish in color, it 
extended retroperitoneally across the posterior abdominal wall from the 
second part of the duodenum to the spleen. The right side of the organ 
(called the head) is encircled by the duodenum, the tapered left side extends 
slightly upward (called the body of the pancreas) which forms the main bulk 
of the organ, ends in the tail that lies in contact with the spleen (Kumar and 
Clark, 2002). 
1.1.2 Pancreas histological structure: 
The pancreas consists of exocrine and endocrine cells making upto 
98% of the human pancreas. The pancreas acinar cells are grouped into 
lobules forming the ductal system which eventually joins into the main 
pancreatic duct. The main pancreatic duct itself usually joins the common 
bile duct to enter the duodenum as a short single duct at the ampulla of vater 
(Kumar and Clark, 2002). 
The endocrine pancreas consists of hormone-producing cells arranged in 
nests or islet called the islet of langerhans, the hormones produced are 
secreted directly in the circulation and there is no access to pancreatic 
ductular system (Kumar and Clark, 1988). 
1.1.3 Pancreas function: 
1.1.3.1 Exocrine function: 
  The pancreatic acinar cells are responsible for production of the 
digestive enzymes; these include amylase, lipase, colipase, phospholipase 
and the protease. These enzymes are stored within the acinar cells in 
 4
secretary granules and are released by exocytosis (Kumar and Clark, 2002). 
Most of these enzymes are secreted in the pancreas from which activated in 
the duodenum (Macsween and Whalely 1992). 
1.1.3.2 Endocrine function: 
The islet of Langerhans consist of five main types of cells correspond to 
different secretory component. The B-cells which are most common and 
responsible for insulin production, the α-cells produce glucagon, the D-cells 
produce somatostatin, and pp-cells produce pancreatic polypeptides and the 
enterochromaffin cells produces serotonin. A number of other hormones 
have been identified within the endocrine pancreas including gastrin 
releasing peptide, neuropeptide Y and galanin. These are believed to be 
neurotransmitters in the neurogastrointestinal axis (Kumar and Clark, 2002). 
1.2 Insulin: 
    1.2.1 Structure: 
Insulin is key hormone involved in the storage and controlled release 
within the body of chemical energy available from food. The human insulin 
gene is located on the short arm of chromosome 11 (Murray et al., 2000). 
Insulin is produced in B-cells of pancreatic islets, it is initially synthesized as 
a single chain 86-amino acids precursor polypeptide, insulin consist of A 
and B chains linked together by disulphide bonds (Kasper et al., 2005). 
1.2.2 Secretion: 
The human pancreas secretes 40 to 50 units of insulin daily which 
represent about 15 to 20% of the stored in the gland (Murray et al., 2000). 
Glucose is the key regulator of insulin secretion by the pancreatic beta cell. 
Although amino acids, ketones, various nutrients, gastrointestinal peptide 
and neurotransmitters also influence insulin secretion, glucose levels 70 
mg/dl stimulate insulin synthesis, primary by enhancing protein translation 
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and processing. Glucose stimulation of insulin secretion begins with 
transporter. Glucose phosphorylation by glucokinase is the rate limiting step 
that controls glucose-regulated insulin secretion. Further metabolism of 
glucose-6 phosphate via glycolysis generates ATP, which inhibit the activity 
of an ATP-sensitive K+ channel. Inhibition of this channel induces B cells 
membrane depolarization, which opens voltage dependant Ca++ channels, 
and stimulates insulin secretion (Kasper et al., 2005). 
About 50% of secreted insulin is extracted and degraded in the liver, 
kidney break down the residence, and c-peptide is only partially extracted by 
the liver and hence provides a useful index of the rate of insulin secretion, 
but is mainly degraded by the kidneys (Kumar and Clark, 1988). 
1.2.3 Insulin function: 
         The action of insulin has been known for quite sometime (Steiner, 
1977). The effect of stimulation of insulin receptors includes activation of 
glucokinase and glucose phosphatase. Insulin also increases glucose 
transport as well as its utilization, especially by muscles and adipose tissues. 
The effect of insulin is reduction of blood glucose due to increase glucose 
uptake in the peripheral tissues, and reduction of hepatic output of glucose 
(diminished break down of glycogen and diminished gluconeogensis). In 
addition to enabling glucose to pass across the cell membrane, the transit of 
amino acids and K+ is enhanced. Insulin regulates carbohydrates utilization 
and energy production. It enhances proteins synthesis and inhibits fat 
degradation (Bennet and Brown, 2003).  
1.2.4 Other pancreatic hormones function:  
Three other pancreatic hormones are produced in the islet of langerhans 
include: glucagon, consisting of 29 amino acids produced by the α cell. 
Somatostatin consisting of 14 amino acids and produced by the D cell. 
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Pancreatic polypeptides, 36 amino acids with an amide C-terminal, produced 
in the PP cell. Glucagon antagonizes most of insulin,s actions, while 
stimulating insulin secretion. Somatostatin inhibits the three other islet 
hormones and a range of hormones from different origins. Pancreatic 
polypeptide inhibits pancreatic secretion altogether (Johnston et al., 1988). 
1.3 Diabetes mellitus (DM): 
Diabetes mellitus (DM) is a clinical syndrome characterized by 
chronic hyperglycemia due to absolute or relative insulin deficiency. This 
can arise in many different ways but commonly due to autoimmune type 1 or 
to adult onset type 2. Lack of insulin affects the metabolism of 
carbohydrates, proteins and fats and can cause a significant disturbance of 
water and electrolyte homeostasis (Boon et al., 2006). 
DM occur world wide and the incidence of both types are rising, it is 
estimated that in year 2000, 171 million people had diabetes, and this is 
expected to double by 2030. This global pandemic principally involve type 1 
and type 2, to which several factors contribute, including greater longevity, 
obesity, unsatisfactory diet, sedentary life style and increasing urbanisation 
(Boon et al., 2006). 
1.3.1 Classification of DM: 
The classification of DM is important because of the different genetic 
backgrounds, clinical presentation, metabolic effects, treatment and 
consequences of the two types. DM may also be secondary to other disorders 
(Forbes and Jackson, 2003). 
Most patients can be classified clinically as having either insulin dependant 
DM (IDDM type 1) or non-insulin dependant DM (NIDDM type 2). In 
patient of either type the body doesn't properly process and use certain food 
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staff (Lewis et al,. 1993). 
1.3.1.1 Type 1 DM: 
 Type 1 is caused by absolute deficiency of insulin production (Fowler, 
2007). It is a slowly progressive T-cell mediated autoimmune disease. 
Family studies have produced evidence that destruction of the insulin 
secreting cells in the pancreatic islets takes place over many years. 
Hyperglycemia accompanied by the classical symptoms of DM occurs only 
when 70 - 90% of B cells have been destructed (Boon et al., 2006). 
Although this type 1 DM is more common in childhood, it can occur at any 
time in the life. Adults misdiagnosed as having type 2 rather than type 1 
diabetes may be expected to have very limited or transient response to oral 
agents and to progress rapidly to insulin therapy. Because these patients 
eventually develop an absolute deficiency of insulin, insulin is the mainstay 
of treatment. Progression to absolute deficiency is variable and tends to be 
rapid in children than adults (Fowler, 2007). 
1.3.1.2 Type 2 DM: 
Type 2 DM is heterogeneous group of conditions. Previously this 
group of condition was known as noninsulin dependant DM or adult onset. 
This type can became recognizable at any age, although it can be 
asymptomatic for years and thus usually present in patients over 40 years of 
age. This type involves insulin resistance and relative insulin deficiency. 
Insulin resistance is thought to precede to insulin deficiency in most patients, 
and autoimmune destruction of B cell doesn't occur, although B cell mass 
may be reduced. Because the insulin deficiency is relative rather than 
absolute, diabetic ketoacidosis occurs less frequently than in type1 diabetes 
(Fowler, 2007).        
Characteristic feature of type 2 DM is that it is often associated with obesity, 
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hypertension and dyslipidemia characterized by elevated level of LDL 
cholesterol and triglycerides and low level of HDL cholesterol (Boon et al., 
2006). 
1.3.1.3 Gestational DM: 
Gestational DM is defined as any degree of glucose intolerance with 
onset or first recognition during pregnancy (Fowler, 2007). The risks factors 
for gestational DM are obesity, ethnicity (south Asian, black and native 
Americans), and family history of type 2 DM, previous glucose 
abnormalities in pregnancy and previous macrosomia (Remmers, 1994). 
Some studies have demonstrated that as many as 70% of women who 
experience gestational DM will develop type 2 DM within 10 years after 
delivery (Kim et al., 2002). 
1.3.1.4 Impaired fasting glucose and glucose tolerance: 
There also exist a large group of patients whose glucose is not 
sufficiently elevated to meet the diagnosis of DM by the above criteria, but 
whose glucose is too high to be considered normal. These individuals have 
fasting glucose levels between 100 and 125 mg/dl or 2-hour post prandial 
glucose readings of 140__ 199 mg/dl. These patients are considered to have 
impaired fasting glucose or glucose intolerance respectively (Fowler, 2007). 
These patients may have normal hemoglobin A1C (HbA1c) values and may be 
virtually normoglycemic but are at risk to develop overt diabetes. This risk 
may be reduced significantly by life style changes or some medical therapies 
(Knowler et al., 2003). To date, prevention strategies for type1 DM have not 
been successful (Fowler, 2007). Management of patient with IGT and IFG 
should be aimed at diminishing the risk of metabolic and physical 
deterioration by reducing obesity, hypertension, physical inactivities and 
hyperlipidemia, and by stopping smoking. In pregnancy IGT should be taken 
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seriously and treated as gestational DM (Forbes and Jackson, 2003). 
1.3.1.5 Other specific types of diabetes: 
 The American diabetes association (ADA) in 2007 recognizes more 
than 56 other specific types of diabetes. Some of these are quite rare, 
whereas others are much more common. The other form of diabetes 
associated with insulin deficiency with non- immune mediated injury to the 
B-cell or the pancreas as whole; include cystic fibrosis, acute or chronic 
pancreatitis, trauma, partial or complete resection and other causes. Several 
hormones oppose the action of insulin and are therefore diabetogenic if 
secreted in excess, such as cortisol (Cushing’s syndrome), growth hormone 
(acromegaly), glucagons (pancreatic glucagonoma) and epinephrine 
(pheochromocytoma) (Knowler et al., 2002). 
 Many of these hormone lead to hyperglycemia by increasing hepatic 
synthesis of glucose or decreasing insulin sensitivity. Condition that cause 
excess secretion of these substances can result in glucose tolerance, elevated 
fasting glucose, or frank diabetes. It is important to note unusual physical 
stigmata of these diseases when evaluating patients for diabetes, especially if 
they are newly presenting, exhibit more rapid prognosis or are resistant to 
therapy, some estimates suggest that up to 3% of patients with poorly 
controlled glucose in diabetes clinics may have Cushing’s syndrome 
(leibowitz et al., 2002). 
Several monogenetic defects in the B-cell function have been described. 
They are collectively referred to as maturity onset of DM of the young 
(MODY). Typically, they manifest themselves in the infancy or childhood, 
because impaired insulin secretion with relatively normal insulin action, and 
are inherited in an autosomal – dominant fashion. In 2007 the American 
diabetes association reported there are also several genetic disorders that 
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lead to abnormal insulin action, examples include lep-rechunism, type A 
insulin resistant and Rabson-menunhall syndrome. It is very important to 
accurately diagnose patient with correct form of diabetes to start with 
therapy that are concordant with their underlying defect. In the case of type 
1 DM, early diagnosis and treatment can lead to prolonged ability to produce 
insulin endogenously and lower risk of microvascular complications (Linn et 
al., 1996).  
1.3.2 Biochemical changes associated with DM: 
1.3.2.1 Metabolic disturbance in type 1 DM:     
Patients with type 1 DM present when progressive B-cell destruction 
has crossed a threshold at which adequate insulin secretion and normal blood 
glucose levels can no longer be sustained. The elevated blood glucose is 
known as hyperglycemia which leads to glucosuria and dehydration, which 
in turn induce secondary hyperaldosteronism. Unrestrained lipolysis and 
proteolysis result in weight loss. Increased gluconeogensis and ketogensis, 
when the generation of ketone bodies exceeds the capacity for their 
metabolism, ketoacidosis result. Elevated blood H+ ions drive K+ out of 
intracellular compartment, while secondary hyperaldosteronism encourages 
urinary loss of K+. Thus patients usually present with a quite short histories 
of hyperglycemia symptoms (thirst, polyuria, fatigue and infections), and 
weight loss and may have developed ketoacidosis (Boon et al., 2006). 
1.3.2.2 Metabolic disturbance in type 2 DM:  
Patients with type 2 DM have a slow onset of relative insulin 
deficiency, relative small amount of insulin are required to suppress lipolysis 
and some glucose uptakes maintained in muscles so that unrestrained 
lipolysis and proteolysis don’t occur and weight loss and ketoacidosis are 
rare. Glucosuria occur when the blood glucose level exceeds the renal 
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threshold, the severity of the classical osmotic symptoms of polyuria and 
polydipsia are related to the degree of glucosuria, and these symptoms are 
usually mild. In some patients with type 2 DM, presentation is late and 
pancreatic B-cell function has declined to the point where there is profound 
insulin deficiency. These patients may present with weight loss, although 
ketoacidosis remain extremely rare, intercurrent illness e.g. with infections, 
increase the production of center-regulatory hormones such as cortisol, 
growth hormone and catecholamine, this can precipitate an acute 
exacerbation of insulin deficiency and result in more severe hyperglycemia 
and dehydration. A number of other metabolic abnormalities, particularly 
dyslipidemia are common in patients with type 2 DM (Boon et al., 2006). 
1.3.3 Complications of diabetes mellitus: 
The rationale for the treatment of diabetes has hitherto been directed 
to the correction of hyperglycaemia because hyperglycaemia is known to be 
responsible for the symptoms of polyuria and polydypsia in the short term 
and microangiopathic complications in the long term. The correction of 
hyperglycaemia leads to immediate resolution of polyuria and polydypsia, 
while a decline in HbA1C below 7 has been shown to predict a fall in the rate 
of microangiopathic complications. Thus, glycaemic control is the cardinal 
measure required to prevent microangiopathic complications. However, the 
most important complications leading to mortality in type 2 diabetes is 
macroangiopathy or atherothrombosis. Heart attacks and stroke are 2-4 times 
more frequent in people with diabetes compared with controls, and account 
for 70% of the mortality in these patients. People with diabetes without prior 
myocardial infarction have a similar risk of fatal or nonfatal myocardial 
infarction as non diabetic patients with a previous history of a heart attack. 
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Hyperglycaemia contributes to macrovascular disease but the evidence 
related to its prevention by the control of hyperglycaemia is limited. 
Whereas observational studies demonstrate a relationship between HbA1C 
and cardiovascular events, prospective interventional studies do not show an 
impressive reduction in these events with a fall in HbA1C. Indeed, type 2 
diabetes is not an isolated disease but is rather part of the metabolic (X) 
syndrome in which atherogenic risk factors (obesity, impaired glucose 
tolerance or diabetes, dyslipidaemia, hypertension, hypercoagulability) 
combine with underlying insulin resistance. Moreover, inflammation plays a 
central role in the insulin resistance syndrome and contributes to 
atherogenicity because atherosclerosis is also an inflammatory condition. 
Type2 diabetes should thus be considered first and foremost a macrovascular 
disorder needing to be managed not only by glucose lowering, but also by 
aggressively treating underlying inflammation and associated metabolic 
disorders (Dandona et al., 2003). 
  The restoration of normoglycaemia by the conventional drugs ensures 
the control of diabetic symptoms and the reduction in microangiopathic 
complications. However, the prevention of macrovascular disease, the main 
cause of morbidity in diabetes, involves the use of those glucoselowering 
drugs that have an additional anti-inflammatory effect and the control of 
morbid conditions associated with this disease. It is of great interest that 
insulin thiazolidinediones and metformin not only reduce blood glucose 
concentrations but also exert anti-inflammatory and potential antiatherogenic 
effects. It is also relevant that the common drugs used to treat dyslipidemia 
and hypertension, such as the statins, ACE inhibitors and ARBs, not only 
improve clinical outcomes in type2 diabetes, but also have anti-
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inflammatory properties (Khalil, 2004). 
1.3.4 Principles of management of DM: 
The aim of management is to control symptoms, prevent acute 
metabolic complications of ketoacidosis and hypoglycemia. Encourage self- 
reliance and self-care, prevent or treat complication early and prevent the 
increased morbidity and mortality associated with poorly managed diabetes. 
In type 1 DM, glycemic control is achieved by subcutaneous insulin 
administration two or more times a day (Forbes and Jackson, 2003). 
Since 1922 a lot of research has gone into the improvement of insulin 
therapy both in terms of improved insulin preparation and ease use. 
Achieving purity was the first challenge, Abel discovered insulin could be 
crystallized, which became standard procedure in insulin purification only 
after. Scott (1934) established that Zinc was needed in order to crystallize 
insulin in rhombohedral form, discovery inspired by his observation of Zinc 
in the pancreas; another crystallization step reduced allergic reactions 
(Jorpes, 1949). 
Chromatographic techniques started to play a role in the 1960, leading 
to the first chromatographically purified insulin and mono component of 
insulin (Schlichtkrull et al., 1970). 
Using modified insulin with differing absorption characteristic to 
provide an insulin profile that controls the glycaemia around meals and 
provides a background level for basic metabolic function (Forbes and 
Jackson, 2003).Now a day’s modified insulin can be synthesized by 
recombination of genes used to innate insulin  in E. coli or S. cerevisae, thus 
facilitating structural and functional studies.  
 Dietary modification is essential and involve eliminating simple 
sugars and eating a low fat- high fiber diet with 50% of the calories from 
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carbohydrates, 30% from fats ( mainly polyunsaturated fatty acids) and 20% 
from proteins (Forbes and Jackson, 2003). 
In type 2 DM the main form of treatment is dietary with the emphasis on 
avoiding simple sugars and calories restriction, weight reduction is 
important in most patients with type 2 DM, and only if this cannot be 
achieved and the patient are unacceptably hyperglycemic and or have an 
elevated HbA1c (approximately 7% or higher) should orally hypoglycemic 
agents be added. Sulfonylureas are the first-line treatment in non obese type 
2 DM patients, whereas biguanides have a particular role in the obese 
diabetics. Hyperlipidemia in patients with diabetes requires further 
investigation and control of hyperlipidemia should always be an aim of 
therapy in diabetes (Forbes and Jackson, 2003). 
1.3.4.1 Oral hypoglycemic agents:-  
1.3.4.1.1 Sulfonylureas: 
 They cause hypoglycemia by stimulating release of insulin from 
pancreatic B-cells .They act through a sulfonylurea receptor which is linked 
to a K+ channel on the B-cells surface. K+  transport triggers insulin 
secretion. (Boon et al., 2006). 
These drugs are ineffective in pancreatectomized animals or patient, 
and in diabetic patients who having no endogenous insulin. The 
Sulfonylureas are traditionally divided into two groups or a generation of 
agents. The first group includes tolbutamide, acetohexamide, tolazamide and 
chloropropamide. The second groups include glyburide (Glibenclamide), 
glipizide and glictazide (Gilmans, 1992). 
1.3.4.1.2 Biguanides:-  
     Although their exact mechanism of action remains uncertain, the 
 15
biguanides lower blood glucose concentration by insulin sensitivity and 
peripheral glucose uptake are increased. Perhaps through activation of 
cAMP-regulated kinase in muscle .There is some evidence that it also 
impairs glucose absorption by the gut and inhibits hepatic gluconeogenesis, 
although secretion of some endogenous insulin is mandatory for its glucose 
lowering action, it does not increase insulin secretion and seldom cause 
hypoglycemia. There are two biguanides used in the clinic phenformin and 
metformin, metformin is the only biguanides available (Boon et al., 2006). 
1.3.5 DM in domestic animals: 
DM is frequently found in the dogs (l in 152) and cats (l in 800), 
although it has been reported in horses, cattle, sheep and pigs. The 
fundamental defect in domestic animals is an absolute or relative lack of 
insulin. The animal is unable to utilize glucose. Consequently hyperglycemia 
is constant finding in domestic diabetic animals. Clinical signs typically 
associated with diabetes include polydipsia, polyurea, increased appetite and 
weight loss. The classic signs of ketosis include anorexia, vomiting, 
weakness, lethargy and increase respiratory rate (Coles, 1986). 
1.3.6 Induction of DM by cytotoxic agents: 
Alloxan and streptozotocin are widely used to induce experimental 
diabetes in animal. The mechanism of their action in B cells of the pancreas 
has been intensively investigated and now is quite well understood. The 
cytotoxic action of both these diabetogenic agents are mediated by reactive 
oxygen species, however, the source of their generation is different in the 
case of alloxan and streptozotocin. Alloxan and the product of it’s reduction 
dialuric acid, establish a redox cycle with formation of superoxide radicals. 
These radicals undergo dismutation to hydrogen peroxide. The action of 
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reactive oxygen species with a simultaneously massive increase in cytosolic 
calcium concentration cause rapid destruction of B cells (Szkudellski, 2001). 
1.4  Medicinal plants: 
Recently, many experimental and clinical trials were adopted to detect 
anti hyperglycemic and ant-diabetic effects of many medicinal plants used in 
the folk medicine for the treatment of diabetes mellitus. Earlier studies 
carried by Srinivas et al. (1993) studied the hypoglycemic activity of 
Brassica oleracea var gongylodes in normal and diabetic rats. The aqueous 
extract was administered orally to normal and alloxan- induced diabetic rats, 
the extract showed a significant hypoglycemic activity in both groups of the 
rats. 
 Another study made by Sanchez-de-Medina, (1994) investigated the 
potential hypoglycemic effect of the decoction of Juniperus communis 
berries on normal and streptozotocin- diabetic female Wistar rats. Diabetic 
rats which were given decoction at doses of 125 mg of the total berries /kg 
body weigh for 24 hour, showed a significantly reduced blood glucose 
levels, lost less weight and had a significant lower mortality index compared 
with untreated diabetic animals. Oral administration of the decoction at 
single dose of 250 and 500 mg/kg also decreased the blood glucose levels of 
non-diabetic rats whereas a lower dose of 125 mg/kg had no effect. Studies 
on intestinal glucose absorption, peripheral glucose consumption and 
pancreatic action indicated that the hypoglycemic activity of J. commumis 
berries is due to an increased consumption of peripheral glucose and/or 
increased glucose induced insulin secretion.  
Noor et al. (1989) evaluated the hypoglycemic effect of the aqueous 
extract of the stem of Tinospora crispa in normal and alloxan diabetic rats. 
The hypoglycemic effect was observed in moderately diabetic rats with 
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concomitant improvement in insulinemia. After a 2 week treatment with the 
extract (4 g/l in the drinking water), these rats also showed improvement in 
glucose tolerance. Moreover, acute intravenous treatment with the extract 
(50 mg/kg) caused an increase in plasma insulin levels. The effect of 
Pimpinella anisum seed powder on blood glucose level in normal and 
streptozotocin- diabetic rats was studied by Fath Elrahman (2006). He found 
that there is a significant reduction of the blood glucose in the diabetic rats 
compared to untreated diabetic rats. 
Abass (2008) studied the hypoglycemic activities of Cinnamomum 
verum in normal and hyperglycemic rats. The C. verum powder was 
administered orally to the normal and hyperglycemic rats. The blood glucose 
level was determined 0h, before treatment and at 1, 2 and 4 hours later. The 
C. verum was significantly lowered glucose concentration in the serum of 
hyperglycemic rats compared to untreated diabetic rats. 
1.4.1 Classification of Cinnamomum verum: 
Kingdom:  planate 
Division:    Magnoliophyta 
Class     :    Magnoliopsida 
Order    :   Laurales 
Family   :   Lauraceae 
Genus    :   Cinnamomum 
Species   :  Cinnamomum. verum J.s. Presl 
Synomons name: Cinnamomum zeylanicum 
English name     : Cinnamon, Ceylon cinnamon, Chinese cinnamon 
Arabic name      : Algerfa  
The name cinnamon comes from Greek kinnamonom, itself 
ultimately from Phoenician. The botanical name for the spice-Cinnamomum  
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 Figure 1:  Cinnamomum verum bark 
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zeylanicum- is derived from Srilanka`s former colonial name, Ceylon 
(Encyclopedia, 2008). 
1.4.2 Plant origin: 
               The  member  of the  family  Lauracae   can  be  found     throughout  
 tropical and subtropical regions of the world, Primary in the lowland to 
mountains rain forests.  The main centers are in the Southeast Asia and 
tropical America. Lauracae family includes about 32 genera, and 2500 species 
(Heywood et al., 1971).     
1.4.3 Plant description: 
Cinnamon, Cinnamomum spp, is an aromatic spice isolated from the 
inner bark of the cinnamon trees. It is a green tree all the seasons of the year, 
its height is about 12 meters and it has horizontal branches.It has simple and 
ovate leaves, and yellow or white flowers. Its fruits are globe or ovate shaped 
(Elgazali et al., 1998). 
1.4.4 Active ingredient of Cinnamomum spp: 
Cinnamomum spp. bark contains, between 0.5—4% essential oil 
containing 80% cinnamaldehyde, up to 10% eugenol and 5-10% 
transcinnamic acid; 4-10% phenolic compound; condensed tannins; catechins; 
oligomeric proanththcyanidins; other monoterpenoid including limonene and 
α- terpinol; sesquniterpenoid including pinene; calcium monoterpenoid 
oxalate; gum; mucilage; resin; starch; sugar and trace of coumarin (Mancini et 
al., 1998). 
1.4.5 The uses of C. verum: 
Cinnamon bark is widely used as a spice. It is principally employed in 
cooking as condiment and flavoring material (Encyclopedia, 2008). In 
medicine it acts like other volatile oils and once had a reputation as a cure for 
colds. It has also been used to treat diarrhea and other problem of digestive 
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system (Felter, 2007; Shan et al., 2005; Mancini et al., 1998). The essential 
oil of cinnamon also has antimicrobial properties (Lopez et al., 2005), and it 
can aid in the preservation of certain food (George, 2007). Cinnamon has 
been reported to have remarkable pharmacological effects in the treatment of 
type 2 DM and insulin resistance. Recent advancement in phytochemistry has 
shown that it is acinnamtannin B1 isolated from C. zeylaanicum which is of 
therapeutic effect on type 2 DM (Taher et al., 2008). Cinnamon has 
tradionally been used to treat toothache and fight bad breath and its regular 
use is believed to stave off common cold and aid digestion (Alice Hart, 2007). 
Cinnamon is also used as an insect repellent (Beck, 2006). 
1.4.6 Model of cinnamon effects: 
Cinnamon polyphenols (CP) affect multiple steps related to glucose and 
insulin function. CP activates insulin receptors by increasing their tyrosine 
phosphorylstion activity and by decreasing phosphatase activity that 
inactivate the insulin receptors (Imparl- Radosevich, 1998). CP also increases 
glycogen accumulation (JarvilloTayor et al., 2001). CP also increases the 
amount of the early-response antiinflammatory proteins, tri tetra protein (Cao 
et al., 2007). All these activities and other potential activities may eventually 
lead to more efficient glucose transport and utilization. In addition, CP-
induced tri tetra accumulation may provide one of the molecular bases for the 
beneficial effects of cinnamon in improving the condition of individuals with 
metabolic syndrome and insulin resistance by down regulating the synthesis 
of proinflammatory cytokines. It has also been reported that improvement in 
postprandial blood glucose response are related to gastric emptying rate but 
that the effects on postprandial glucose are greater than those on gastric 
emptying rate (Hlebowicz et al., 2007). 
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1.4.7 Biological activities:               
1.4.7.1 Anti-clotting action: 
Cinnamaldehyde (also called cinnamic aldehyde) has been well 
researched for its effects on blood platelets which are constituents of blood 
that are meant to clump together under emergency circumstances (like 
physical injury) as a way to stop bleeding, but under normal circumstances  
they can make blood flow inadequate if they clump together too much. The 
cinnamaldehyde in cinnamon helps prevent unwanted clumping of blood 
platelets. The way it accomplishes this health-protective action is by 
inhibiting the release of aninflammatory fatty acid called arachidonic acid 
from platelet membrane and reducing the formation of an inflammatory 
messaging molecule called thromboxane A2. Cinnamon’s ability to lower the 
release of arachidonic acid from cell membrane also puts it in the category of 
an antiinflammatory food that can be helpful in losing inflammation 
(Takenaga, 1987). 
1.4.7.2 Antibacterial effect of cinnamon:    
The antibacterial effect of Cinnamomum spp was identified in a laboratory 
experiment in which pure Cinnamomum cassia extract, mainly composed of 
the active ingredient cinnamaldehyde, was tested on isolated strains of 
bacteria, including Gram positive Staphylococcus aurus, Gram negative E. 
coli, Enterobacter aerogenes, Proteus vulgaris, Pseudomonas aeruginosa, 
Vibrio parahaemolyticuas, and Salmonella typhymurium. The antimicrobial 
effect resulted in a minimum inhibition concentration (MIC) of Cinnamomum 
cassia extract ranging from 75 mcg/ml to 600 mcg/ml on these bacteria (Ooi 
et al., 2006). However, conflicting data was obtained in randomized, 
controlled pilot clinical trail of 15 patients ages 16 to 79 who had a positive 
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Campylobacter urease test for Helicobacter pylori. Each patient in the control  
group received of 40 mg ethanol extract of cinnamon twice daily for four 
weeks; the control group received plain 95% ethanol. With urea breathe test 
as the measurement of efficacy, the mean urea breath test before and after the 
study for the treated group were 22.1 and 24.4, respectively; the mean urea 
breath test before and after the study for the controlled group were 23.9 and 
25.9, respectively. This conclusive study found that 40 mg of cinnamon 
extract given twice daily was ineffective in eradicating Helicobacter pylori 
(WHfoods, 2007, Nir et al., 2000).  
1.4.7.3 Antifungal: 
 Cinnamon oil has been reported as an antifungal agent, although 
current efficacy of cinnamon oil’s fungicidal effect has not been tested in 
clinical trails. Experimentally, promising result on it’s antifungal effect were 
reported in two in vitro studies of cinnamon oil on Cryptococcus neoformans 
and Aspergillus niger. Cryptococcus neoformans is an opportunistic fungal 
pathogen affecting the lungs or meninges of immune compromised or AIDS 
patients, causing pulmonary Cryptococcosis meningitis (Lee et al., 2005). It 
was found that the phenolic compounds in cinnamon oil identified as eugenol 
is responsible for it’s fungitoxic activity (Viollon and Chaumont., 1994).        
Property was again demonstrated in more recent in vitro Aspergillus niger (A. 
niger), an opportunistic fungal pathogen residing in the air, through inhalation 
of Aspergillus sp. spores, entering the respiratory tract of patients with AIDS 
or with immune compromised condition to cause Aspergillosis ( Beers and 
Berkow, 2006). Among the 75 botanical essential oils used, Cinnamomum 
zeylanicum and Cinnamomum cassia demonstrated maximum and superior 
results; the zone of hyphal growth inhibition and the zone of spore formation 
were 43 and 40 versus 50 and 45 for Cinnamomum zeylanicum and 
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Cinnamomum cassia respectively (Pawar and Thaker, 2006). 
1.4.7.4 Antioxidant:     
 There is more to cinnamon beside the antimicrobial, antiinflammatory, 
and antifungal effects attributed to cinnamaldehyde found in Cinnamomum 
cassia powder and oil. The presence of oligomeric proanthocyanidins (OPC), 
a class of bioflavonoid, opened a new area of research on antioxidant effect. 
Through agriculture research, type A and type B oligomeric 
proanthocyanidins were identified in cinnamon spice via mass spectrometer 
analysis. Additionally, it was found that over 84% to 90% of OPC found in 
cinnamon spice were type A OPC (Gu et al., 2003). However, there has not 
been a specific study on the antioxidative effect of cinnamon alone. 
Antioxidants are essential to the human body to neutralize free reactive 
oxygen species, also known as free radicals, to maintain the functional 
cellular membrane and structure. Furthermore, free radical associated with 
impaired glucose metabolism and antioxidants have been implicated in the 
regression of DM. 
1.4.7.5 Antiinflammatory: 
 Although cinnamon historically had not been used to treat 
inflammatory disorders, its antiinflammatory effect was demonstrated 
experimentally. Specifically, Cinnamomum cassia was used to investigate 
the anti-inflammatory effect on nitric oxide (NO) and nuclear factor kappa-
b. Both substances have been implicated in inflammation. In acute and 
chronic inflammation, there is an increased production of NO, which 
promotes vasodilatation and results in increased vascular permeability and 
edema. NO also activates COX-2 enzymes involving in the biosynthetic 
pathway of inflammatory prostglandins (Thomas et al., 2004) .Nuclear 
factor kappa-b contributes to inflammation through induction of 
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transcription of genes coding for inflammatory mediators. It was found that 
cinnamaldehyde, specifically 2`hydroxycinnamaldehyde found in 
Cinnamomum cassia extract, exhibited a dose dependant inhibitory effect on 
NO production and transcriptional activity of NF-KB, thereby contributing 
to it’s antiinflammatory qualities (Lee et al., 2005). 
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CHAPTER TWO 
MATERIAL AND METHODS 
This work was conducted in the Department of Pharmacology, 
Medicinal and Aromatic Plants Research Institute (MAPRI), National Center 
For Research, Khartoum and Research Laboratory Unit, Khartoum Teaching 
Hospital.                                                                                
2.1 Materials: 
2.1.1 Experimental animals: 
Twenty Wistar albino rats obtained from the National Center for 
Research, Khartoum were used in this study. The rats were housed 
identically in stainless steel cages in an air conditioned room under suitable 
conditions. All rats were initially fed a standard laboratory diet for at least 7 
days to acclimatize to the laboratory. Tap water was freely available. Then 
the rats were divided into four groups of five rats each on the basis of body 
weight so as each group had body weight range of 95 - 200g. 
2.1.2 Plant material: 
Cinnamomum verum bark was purchased from local market, identified 
authenticated (Elgazali et al., 1998), peeled in fine pieces of various sizes and 
was powdered. 
2.1.3 Feeding program: 
    Each group was kept in a cage and was supplied with feed composed    
of meat, wheat flour, carrot and salt. 
     The feed was available at the rate of 36 g per day in each cage. 
2.1.4 Experimental induction of diabetes:   
         Two groups (C and D) of rats were injected intraperitoneally with 
alloxan monohydrate dissolved in sterile normal saline at a dose of 150 mg 
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/kg body weight (El-Dokhakhny et al., 2000) to induce diabetes mellitus. 
After that, the diabetic rats were used for the experiment. 
2.1.5 Experimental protocol: 
The rats were divided into four groups of five rats each. These groups were 
named as A, B, C, and D. The experimental is shown in Table 1.   
 Group A: 
             The rats of group A was given basal diet for 21 days and served as 
control. 
Group B:  
The rats of group B was given orally Cinnamon bark powder 
suspended in distilled water at dose of 1g/ kg body weight by small rubber 
tube for 21 days. 
Group C:  
            Alloxan induced diabetic rats was given basal diet for 21 days and 
served as control. 
Group D: 
           Alloxan induced diabetic rats received orally by small rubber tube 
1g/kg body weight of Cinnamon bark powder suspended in distilled water for 
21 days. 
Blood samples were collected from the four groups on day 1, 3,21and 22 from 
the beginning of the treatment.  
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Table 1: Experimental design and feeding program: 
Description  Group A Group B Group C Group D 
Number of rats 5 5 5 5 
Induction of diabetes mellitus - - + + 
Oral administration of C.verum - + - + 
 
2.1.6 Instruments: 
The Roch diagnostic/Hitachi 92 analyzer 
IEG-CENTRA-4B centrifuge 
Finn pipette, digital micropipette, was used for pipetting of serum samples. 
Heparinized capillary tubes 
Heparinized container 
Fluorinated container 
A sterile plain container was used for blood collection.  
2.1.7 Chemicals: 
Alloxan 
Sodium chloride 0.85 (normal saline) 
Glucose 50 % solution 
2.1.8 Blood sampling: 
       One and half ml of blood was collected from orbital plexus of rats after 
fasting for 18 h by heparinzed capillary tubes and was put in heparinzed 
containers; the blood was centrifuged at 5000 rpm for 10 minutes. Then the 
plasma was kept into plain containers and used for estimate plasma glucose. 
Blood samples from each rat at day zero and 3 were collected to estimate 
blood glucose level for checking whether the diabetes was induced by 
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alloxan injection or not. 
  At day 21st the blood was collected from the rats after fasting for 18 
hours to determine the level of plasma glucose at 0 h, then rats were injected 
50% glucose at dose of 2g /kg body weight and blood was collected to 
monitor plasma glucose level at 1 h and 2 h after glucose was given. At day 
22nd rats were sacrificed and the blood was collected from jugular vein of 
each rats. The blood was collected in fluorinated containers; and centrifuged 
at 5000 rpm for 10 minutes. The collected plasma was kept into plain 
containers and used to estimate the biochemical parameters. 
2.2. Analytical methods: 
2.2.1. Glucose tolerance test: 
            Glucose tolerance test were indicated as a confirmatory method for 
the diagnosis of deviations in normal glucose metabolism. It was determined 
by evaluating the concentration of blood glucose at specific intervals before 
and after the intravenous administration of a given quantity of glucose. In 
the glucose tolerances test 2g of glucose /kg. body weight was injected  
intravenously as a 50% solution after a standard 24 hour fast (Coles, 1986). 
2.2.2. Roche diagnostic/Hitachi 902 analyzer: 
All biochemical parameters were estimated using the Roche diagnostic 
Hitachi 902 analyzer. It is an analyzer to report test results on various body 
fluid samples for wide range of analysis. It is fully automated, computerized, 
performs potentiometric and photometric assays. It includes analytical 
processing unit and luminance crystal display (LCD) touch screen, with a 
standard printer to print the results. The analyzer is characterized by doing 
200 photometric tests/ hour, and refrigerated storage for 40 reagent 
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containers, as well as it has end point, and kinetic and isoenzymes reactions. 
2.2.3 Determination of Glucose: 
         Glucose concentration in the plasma was determined by enzymatic 
method as described by Trinder (1969).  
Principle: 
In the presence of glucose oxidase, glucose is oxidized to gluconic acid 
and hydrogen peroxide. Hydrogen peroxide reacts, in the presence of 
peroxidase, with phenol and 4-aminophenazone to form aquinoneimine dye. 
The intensity of the pink color formed is proportional to the glucose 
concentration.    
Glucose + O2        glucose oxidase           gluconic acid +H2 O2        
2H2 O2 + 4-Aminophenazone + Phenol  
peroxidase       Quinoneimine + 4H2O2      
Reagents:   
     . Phosphate buffer (pH 7.5)                       0.1 mol/L 
   .  Phenol.                                                   0.75 mmol/L 
     .  4-aminophenazone.                                 0.25 mmol/L 
     . Glucose oxidase.                                     15 ku/L                                                               
     .  Peroxidase.                                             1.5 ku/L                                                               
Procedure: 
    The analyzer automatically added an equal quantity from sample 
and reagents to the reaction. 
Calculations: 
           The analyzer automatically calculated the analyte concentration 
of each sample. The result appeared directly on the screen of the diagnostic 
machine at the end of the reaction between the reagents and samples. 
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2.2.4 Total cholesterol estimation: 
           The cholesterol concentration was estimated by an enzymatic method 
which measures the total cholesterol concentration in the plasma, or 
heparinzed blood as described by Richmond (1973) .  
Principle: 
In the presence of cholesterol esterase, the cholesterol esters in the 
sample are hydrolyzed to cholesterol and free fatty acids. The cholesterol 
produced is oxidized by cholesterol oxidase to cholesterol-3-one and 
hydrogen peroxide. Hydrogen peroxide is detected by chromogenic oxygen 
acceptor, phenol – ampyrone, in the presence of peroxidase. The red quinine 
formed is proportional to the amount of cholesterol present in the sample.  
Reagents: 
       Reagent (R1)   
          .   Buffer pH 6.9                             90 mmol/L 
          .   Phenol                                         26 mmol/L 
      Reagent (R2)  
          .  Cholesterol esterase                      300 u/L 
          . Cholesterol oxidase                       300 u/L 
          .  Phenol- ampyrone/ peroxidase     1250 u/L 
          .  4 – Aminoantipyrine                     0.4 mmol/L  
Procedure: 
The analyzer automatically added an equal quantity from sample, R1 
and R2 to the reaction. 
Calculations: 
The analyzer automatically calculated the analyte concentration of 
each sample. The result appeared directly on the screen of the diagnostic 
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machine at the end of the reaction between the reagents and samples. 
2.2.5 Low density lipoprotein-cholesterol (LDL-c) estimation: 
LDL-c particles in the sample are precipitated with polyvinyl 
sulphate. Their concentration is calculated from the difference between the 
serum total cholesterol and the cholesterol in the suprnatant after 
centrifugation. The cholesterol is spectrophometrically measured by means 
of the coupled reactions as described for cholesterol (Assmann et al ., 1984). 
Principle: 
In this method LDL-cholesterol is selectively protected from 
lipoprotein lipase by protecting reagent (R1), then in the second step LDL-
cholesterol is released and selectively determined by releasing reagent (R2). 
Cholestrol ester + H2O      cholestrol esterase              cholesterol + fatty acid. 
Cholesterol+1/2 O2 +H2O      cholestrol oxidase           cholesterol+ H2O2  
          2H2 O2 + 4-Aminophenaone + Phenol     peroxidase       Quinoneimine (blue     
          color  complex) + 4H2O2   
Reagents: 
 
Reagent (R1)  
       . Goodۥs buffer pH (6.8).               25 mmol/L 
       . Cholestrol esterase.                     5000 u/L 
       . Cholestrol oxidase.                      5000 u/L 
       . Catalase.                                      1000 ku/L 
Reagent (R2)    
   .  Goodۥs buffer pH (7.0).              25 mmol/L 
   . 4-aminoantipyrine.                       3.5 mmol/L 
   . Peroxidase.                                  20 ku/L 
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Procedure:  
The analyzer automatically added an equal quantity from sample and 
reagents to the reaction. 
Calculations: 
The analyzer automatically calculated the analyte concentration of 
each sample. The result appeared directly on the screen of the diagnostic 
machine at the end of the reaction between the reagents and samples. 
2.2.6 High density lipoprotein-cholesterol (HDL-c) estimation: 
Principle: 
When serum is combined with the polyethylene glycol reagent, all 
beta – lipoprotein (LDL and VLDL) are precipitated. The HDL fraction 
(alpha-fraction) remains in the supernatant. The supernatant is then treated 
as a sample and assayed for cholestrol by an enzymatic method. The value 
obtained is the HDL- cholestrol value.  
Reagents: 
HDL -cholestrol Precipitating Reagent : 
     . 20% w/v polyethylene glycol in glycine buffer at pH 10, 0 (25cº) 
 
Procedure: 
The analyzer automatically added an equal quantity from the sample 
and reagents to the reaction. 
Calculations: 
The analyzer automatically calculated the analyte concentration of 
each sample. The result appeared directly on the screen of the diagnostic 
machine at the end of the reaction between the reagents and samples. 
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2.2.7 Triglycerides estimation: 
Principle: 
Triglycerides in the sample are hydrolyzed enzymatically to glycerol 
and fatty acids. The glycerol formed is converted to glycerol phosphate by 
glycerol kinase. Glycerol phosphate is oxidized to dihydroxyacetone 
phosphate by glycerol phosphate oxidase. The liberated hydrogen peroxide 
is detected by a chromogenic acceptor, chlorophenol and 4-amino antipyrine 
in the presence of peroxidase. The red quinone formed is proportional to the 
amount of triglyceride present in the sample.  
Reagents: 
  Reagent (R1)     
    .  Buffer                                               45 mmol/L 
    . Chlorophenol                                     6 mmol/L  
  Reagent (R2)  
   .  Magnesium chloride                          5 mmol/L 
   .  Lipase                                                100 u/ mL 
   .  Glycerol kinase                                  1.5 u/mL 
   . Glycerol -3- oxidase phosphate         4 u/ mL 
          .  Peroxidase                                          0.8 u/mL                                            
          . 4- aminoantipyrine                              0.75 mmol/L 
  . ATP                                                     0.9 mmol/L 
  . pH                                                        7.5 
 
Procedure: 
The analyzer automatically added an equal quantity from sample, R1 
and R2 to the reaction. 
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Calculations: 
The analyzer automatically calculated the analyte concentration of 
each sample. The result appeared directly on the screen of the diagnostic 
machine at the end of the reaction between the reagents and samples. 
2.2.8 Determination of plasma total protein: 
Principle: 
          Cupric ions in an alkaline solution react with the peptide bonds of 
proteins and polypeptides containing at least two peptide bonds to produce a 
violet colored complex. The absorbance of the complex at 546 nm is directly 
proportional to the concentration of protein in the sample. 
CU     + Protein        OH¯             Cu-protein complex 
Reagents:  
          Reagents (R1)  
.  Sodium hydroxide                             3.8 mol/L 
.  Potassium sodium tartarate               100 mmol/L 
. Copper sulphate                                 30 mmol/L 
. Potassium iodide                                30 mmol/L  
         Reagents(R 2)  
          . Standard: bovine serum albumin             
Procedure: 
         The analyzer automatically added an equal quantity from 
sample, R1 and R2 to the reaction. 
  Calculation: 
The analyzer automatically calculated the analyte concentration of each 
sample. The result appeared directly on the screen of the diagnostic machine 
at the end of the reaction between the reagents and samples. 
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2.2.9 Determination of plasma albumin: 
Principle: 
          At pH= 4.2, albumin bind with bromocresol green to produce a blue –
green complex. The change in absorbance at 628 nm correlates with the 
concentration of albumin. 
Reagents: 
          Reagents(R 1) 
         .  Bromocresol green                                    0.15 mmol /L 
     .  Succinate buffer (pH 4.20)                       75   mmol / L 
     .  Brij 35                                                       7   ml /L  
         Reagents(R 2) 
     .   Albumin standard                                       50 g/L                                                   
Procedure:  
        The analyzer automatically added an equal quantity from sample, R1 
and R2 to the reaction. 
Calculation:  
          The analyzer automatically calculated the analyte concentration of 
each sample. The result appeared directly on the screen of the diagnostic 
machine at the end of the reaction between the reagents and samples. 
2.2.10 Determination of bilirubin: 
Principle: 
Sulphnilic acid reacted with sodium nitrite to form diazotized 
sulfanilic acid .In the presence of dimethylsulfoxide, total bilirubin reacted 
with diazotized sulfanilic acid to form azobilirubin .In the absence of 
dimethylsulfoxide, only the direct bilirubin reacts to give azobilirubin. The 
absorbance measured at 555nm is proportional to the bilirubin concentration.      
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Reagents: 
Reagent (R1)  
.  Sulphanilic acid                                     3.2 mmol/L  
. Hydrochloric acid                                  165 mmol/L  
. Dimethylsulfoxide                                 7    mmol/L 
Reagent (R2)   
.Sodium nitrite                                          8.6 mmol/L 
Procedure: 
          The analyzer automatically added an equal quantity from sample, R1 
and R2 to the reaction. 
Calculation: 
                    The analyzer automatically calculated the analyte concentration 
of each sample. The result appeared directly on the screen of the diagnostic 
machine at the end of the reaction between the reagents and samples. 
2.2.11 Determination of alanine aminotransferase (ALT): 
Principles: 
ALT catalyses the transformation of L-Alanine and 2-oxoglutarate 
at optimal pH . The pyruvate released in the reaction is transformed by 
Lactate dehydrogenase (LDH) in the presence of NADH/NAD coenzyme to 
L-lactate .While the NADH/NAD oxidoreductive process shows a decrease 
in absorbance at 340nm .The change in absorbance correlates with serum 
ALT activity. 
    L-Alanine + α-Ketoglutarate         ALT             pyruvate-L-Glutamate 
    Pyruvate   +     NADH                 LDH               L-Lactate-NAD  
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Reagents:   
               Reagents(R1)  
     . Tris buffer, pH: 7.50                          110 mmol/L 
     .   L-Alanine                                         600 mmol/L 
     .  LDH                                                  1500u/L 
     . NADH                                               240 mmol/L 
             Reagents(R2)  
              . α-Ketoglutarate                                   16 mmol/L                          
Procedure: 
            The analyzer automatically added an equal quantity from sample, R1 
and R2 to the reaction. 
Calculation:  
            The analyzer automatically calculated the analyte concentration of 
each sample. The result appeared directly on the screen of the diagnostic 
machine at the end of the reaction between the reagents and samples. 
2.2.12 Determination of aspartate amino transferase (AST): 
Two substrate participate in the reaction catalyzed by AST .L-
aspartate and oxolglutarate (With the help of NADH  coenzyme) .Malate 
dehydrogenase (MDH) contained in the reagent catalyses the transformation 
of oxalacetate released in the first reaction .The oxido-reductive process of 
NADH/NAD is indicated by a decrease in absorbance at 340 nm.The lactate 
dehydrogenase (LDH) in the medium counteracts the disturbing effect of 
pyruvate contained in the sample.  
L-Aspartate + α-Ketoglutarate       AST             L-glutamate -Oxalacetate    
Oxalacetate  +   NADH             MDH                 L-Malate -NAD                      
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Reagents: 
          Reagents (R1) 
     . Tris buffer, pH: 7.80                     88   mmol/L 
     . L-Aspartate                                   260 mmol/L 
     . LDH                                              1500   u/L 
     . MDH                                             900   u/L 
    .  NADH                                            0.24 mmol/L 
          Reagents (R2) 
         . α-Ketoglutarate                               12   mmol/L 
Procedure: 
            The analyzer automatically added an equal quantity from sample, R1 
and R2 to the reaction. 
Calculation: 
           The analyzer automatically calculated the analyte concentration of 
each sample. The result appeared directly on the screen of the diagnostic 
machine at the end of the reaction between the reagents and samples. 
Quality Control: 
The precision and accuracy of all methods used in this study were 
checked each time a batch was analyzed by including commercially prepared 
control sera. 
2.2.12 Statistical analysis: 
According to completely randomized design the rats were divided into four 
groups (A,B,C and D) .Each group contain 5 rats of similar body weight .The 
data were analyzed by one and two way ANOVA procedure according to SAS 
software . Each test was conducted at 5% level of significant .Means were 
separated by multiple comparisons range test.  
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CHAPTER THREE 
RESULTS 
 
 3.1 The effect of Alloxan injection on plasma glucose concentration:-      
       When Wistar albino rats were injected with Alloxan , the plasma 
glucose concentration in day 3 increased significantly for group  C , D while 
the glucose level at day 3 of control groups A , B  remained the same as day 
zero as shown in Figure 3 . 
3.2 The effect of oral administration of C.verum on plasma glucose 
tolerance or after high glucose dose application of normal and diabetic 
rats:- 
     When C.verum powder was administrated orally to normal and diabetic 
rats for 21 days, the plasma glucose level measured at 0h, 1 and 2 after 
fasting are shown in Table 2. 
At 0h, there was no significant difference in glucose level between normal 
rats (Group A) and normal rats given orally C. verum powder (Group B), 
(79.00 Vs 112.80).The glucose level of diabetic rats was significantly higher 
than glucose level of normal rats (Group A) and normal rats given orally C. 
verum (Group B). The glucose plasma concentration of diabetic rats 
administrated orally with C.verum (Group D) was significantly lower than 
glucose concentration of diabetic rats (Group C) but significantly higher 
than normal control and non significantly higher than normal given C.verum. 
After 1 hour, the plasma glucose concentration of normal rats given orally 
C.verum (Group B) was not significantly different from that of the normal 
control rats (127.00 Vs 110.00). While the glucose concentration of diabetic 
rats (Group C) was significantly higher than normal control rats, normal rats  
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Figure 3: plasma glucose level at day 0 and day 3 after alloxan  
                           injection 
 
        Bars with different letters are significantly different (P≤0.05) 
 
       Group A :  Normal control rats 
       Group B :  Normal rats administrated with C.verum 
       Group C :  Alloxan induced diabetic rats 
       Group D : Alloxan induced diabetic rats administrated with C.verum 
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Table (2): The effect of oral administration of C. verum for 21 day on 
plasma glucose concentration of normal and diabetic rats after 
application of 50% glucose dose:  
Sampling 
Time 
Plasma glucose (mg/dl) of group:  
 
Probability              
A    
 
B 
 
C 
 
D 
0 h 79.00a±5.25 112.80ab±2.96 233.33c±37.40 138.40b±18.00 
      
  
0.0002         
1 h  110.00a±9.67 127.00ab±9.26 284.67c±27.50 182.80b±30.70 
      
 
0.0004           
2 h 97.60a±10.50 108.50a±8.66 264.00c±22.90 177.60b±26.30 
      
 
0.0003 
 
Data are expressed as mean ± standard error 
Mean values having different superscripts (small letters) within the same 
row differ significantly at P≤0.05. 
Group A: Normal control rats 
Group B: Normal rats administrated with C.verum 
Group C: Alloxan induced diabetic rats  
Group D: Alloxan induced diabetic rats administrated with C.verum 
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administrated orally with C.verum and diabetic rats administrated orally with 
C.verum. Also , at 1h , the plasma glucose level of diabetic rats given orally 
C.verum was higher significantly than plasma glucose level of normal 
control rats and non significantly than normal rats administrated orally with 
C.verum. It was noticed the glucose of normal control rats increased 31 mg 
in each dl while in normal rats given C.verum, the increase was 15 mg in 
each dl, 1h after glucose was given.  
At 2h, the plasma glucose level of normal control and normal rats 
administrated orally with C.verum were not different significantly but they   
were significantly lower than diabetic rats and diabetic rats administrated 
orally with C.verum. The plasma glucose concentration of diabetic rats 
administrated orally with C.verum was significantly lower than diabetic rats. 
It was also noticed, the glucose level of normal rats decreased 13 mg in each 
dl while that of normal rats given C.verum decreased 19 mg in each dl, at 2h. 
3.3 The effect of oral administration of C.verum on plasma total protein 
and plasma albumin of normal and diabetic rats:- 
  When C.verum administrated orally to normal and diabetic rats, the 
administration of C.verum had no effect on plasma albumin concentration of 
normal and diabetic rats as shown in Table 3. The level of plasma total 
protein of normal control rats and diabetic rats was not significantly 
different.   
The administration of C .verum significantly decreased the total protein 
concentration of diabetic rats when compared to normal rats administrated 
orally with C. verum, normal rats and diabetic rats, also oral administration 
of C. verum decreased the level of total protein of normal rats when 
compared to normal control rats (Table 3). 
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Table (3): The effect of oral administration of C. verum on plasma total. 
protein, albumin, bilirubin, AST, and ALT of normal and diabetic rats:   
Parameter 
Plasma concentration level of group:  
probability 
A B C D 
      Total. 
Protein 
(g/dl) 
7.66a±0.15 6.63b±0.30 7.73a±0.12 5.64c±0.14 
      
    <.0001 
Albumin  
     (g/dl) 4.24
a±0.73 3.13a±0.13 3.43a±0.22 2.62a±0.08 
            
    0.1161         
Bilirubin 
     Total 
    ( Mg/l)     
0.40a±0.05 0.33a±0.12 0.37a±0.03 0.44a±0.02 
       
    0.6383         
  
AST 
      (U/l) 
297.60a±17.80 411.67b±41.50  241.33a±42.40 314.40a±23.40 
          
     0.0206        
ALT  
(U/l)     67.80
a±9.91 73.00a±4.00 68.67a±6.23 62.40a±4.59 
       
      0.8034       
 
 
Data are expressed as mean ± standard error 
Mean values having different superscripts (small letters) within the same 
row differ significantly at P≤0.05. 
Group A: Normal control rats 
Group B: Normal rats administrated with C.verum 
Group C: Alloxan induced diabetic rats  
Group D: Alloxan induced diabetic rats administrated with C.verum 
 
 
 
 45
3.4 The effect of oral administration of C. verum on AST, ALT    
and plasma bilirubin of normal and diabetic rats: 
      The administration of C. verum had no significant effect on plasma  
concentration of ALT enzymes of normal and diabetic rats. The 
administration of C. verum increased numerically the plasma ALT 
concentration of normal rats (group B) when compared to normal control 
rats (73.00 Vs 67.80). but it decreased numerically the plasma concentration 
of ALT of diabetic rats administrated orally with C.verum when compared to 
diabetic rats (62.40 Vs 68.67). 
 However, the administration of C. verum to normal rats increased 
significantly the plasma concentration of AST when compared with normal 
control rats (411. 67 Vs 297.60) and increased numerically the plasma 
concentration of diabetic rats administrated orally with C. verum when 
compared to normal control rats (314.40 Vs 297.60), and diabetic 
rats(314.40 Vs 241.33).  
The plasma concentration of AST of diabetic was non significantly lower 
than normal (241.33 Vs 297.60).   
The plasma bilirubin concentration was not significantly affected by 
administration of C.verum in normal rats (0.40 Vs 0.33) and in diabetic rats 
(0.37 Vs 0.44)   
 3.5 The effect of oral administration of C.verum on plasma               
concentration of cholestrol, triglyceride, HDL -c and LDL- c of normal 
and diabetic rats:- 
     When C.verum was administrated orally to normal and diabetic rats, the 
effect administration of C.verum on plasma cholestrol concentration is 
shown in Table 4. 
The administration of C.verum decreased significantly the plasma cholestrol  
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Table (4): The effect of oral administration of C.verum on serum 
cholesterol, triglyceride, HDL-c and LDL-c: 
 
Parameter 
Plasma concentration level of group:  
 
Probability  
A 
 
B 
 
C 
 
D 
Cholesterol 
    (mg/dl)      
 
57.00ab±3.48 42.33bc±8.69 69.33a±11.30 36.40c±3.59 
        
 
0.0112           
Triglyceride 
   (mg/dl) 88.20
a±9.24 82.00a±3.06 53.33b±4.41 64.60ab±5.73 
        
 
0.0083           
HDL.C          
(mg/dl) 45.02
a±2.46 31.77b±7.65 37.60ab±2.61 25.92b±1.99 
          
 
0.0072           
 
 LDL.C 
 (mg/dl) 
7.62a±1.61 4.97a±0.98 10.43a±1.21 8.10a±2.37 
         
 
0.4192           
 
Data are expressed as mean ± standard error 
Mean values having different superscripts (small letters) within the same 
row differ significantly at P≤0.05. 
Group A: Normal control rats 
Group B: Normal rats administrated with C.verum 
Group C: Alloxan induced diabetic rats  
Group D: Alloxan induced diabetic rats administrated  
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of diabetic rats when compared to normal control rats and diabetic rats and 
lowered cholestrol level non significantly when compared to normal rats 
given C.verum.   
The plasma concentration of triglyceride of the diabetic rats was 
significantly low when compared to normal control and normal rats given C. 
verum and numerically low when compared to diabetic rats received 
C.verum .The administration of C.verum had significant effect on normal 
and diabetic rats. However, the plasma triglyceride concentration of diabetic 
rats received C.verum (Group D) was numerically lower than normal rats 
and normal rats administrated with C.verum. 
The plasma LDL-c concentration was non significantly lowered when 
C.verum was administrated to normal rats and diabetic rats. The plasma 
LDL-c of diabetic rats was non significantly higher than normal control, 
normal rats received C.verum and diabetic rats received C.verum. 
Also the oral administration of C.verum decreased significantly the 
concentration of plasma HDL-c of normal rats (Group B) when compared to 
normal control rats, and non significantly of diabetic rats administrated 
orally with C.verum (Group D) when compared to diabetic rats (Group C).  
3.6 The effect of oral administration of C.verum on body weight of 
normal and diabetic rats:- 
      The administration of C. verum had no significant effect on body weight    
of normal and diabetic rats. It was noticed there was an increase in body    
weight of Group A (13g) and decrease in group B (7g) , Group C (15g) and 
Group D (6g). 
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Table (5):The effect of oral administration of C. verum on body weight 
of normal and diabetic rats:  
 
Body 
weight 
Groups  
Probability A B C D 
Pre body 
weight 
(g) 
139.00a±17.10 128.00a±5.61 128.33a±1.67 117.00a±9.17 
          
 
 
 0.5712           
    
 Post body      
      weight 
(g) 
 
     
152.00a±16.20 
 
 
      121.00a±7.48 
 
 
   
  113.33a±1.67 
 
 
 
 
 111.00a±10.20 
 
 
                     
 
 0.0780 
    
 
 
Data are expressed as mean ± standard error 
Mean values having different superscripts (small letters) within the same 
row differ significantly at P≤0.05. 
Group A: Normal control rats 
Group B: Normal rats administrated with C.verum 
Group C: Alloxan induced diabetic rats  
GroupD: Alloxan induced diabetic rats administrated with C.verum 
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                                   CHAPTER FOUR 
                                      DISCUSSION 
                                                  
     The current study was carried out to investigate the putative 
hypoglycemic and antidiabetic effect of Cinnamomum verum, one of 
Sudanese flavouring agents. C.verum has antimicrobial activity against 
bacteria and fungi ( Ooi etal .,2006 ; Niretal ., 2006 ; Viollan etal ., 1994 ; 
Beer etal ., 2006 ; Pawar etal ., 2006 ) , and antioxidant activity ( Gu etal ., 
2003 ) . 
Cinnamon as antidiabetic agent , was previously investigated by Khan etal 
.(2003 ) , a pilot clinical trial was conducted in Pakistan to study the effect of 
Cinnamomum cassia powder in patient with type 2 diabetes , average age 
was 52.2  ±  6.32 . The study showed, successful result that Cinnamomum 
cassia reduced fasting serum glucose (18 - 29%). In this study the effect of 
oral administration of C.verum a species closely related to Cinnamomum 
cassia (Wikimedia, 2007)  on normal rats and alloxan induced diabetic rats 
was examined. 
Glucose tolerance test was performed and plasma total protein, albumin, 
cholestrol, triglyceride, bilirubin, liver enzymes and body weight were also 
monitored. 
In this experiment, diabetes mellitus was induced in rats by injection of 
alloxan and the plasma glucose estimation at the 3rd day confirmed that, the 
injection of alloxan induced diabetes mellitus .This agrees with previous 
experiments (El-Dokhakhny etal ., 2001). The diabetogonic effect of this 
cytotoxic agent is mediated by B – cell destruction because of selective 
uptake of the compound due to its structural similarity to glucose as well as 
the beta-cell's highly efficient uptake mechanism (GLUT2) ( Tyrberg, 2001; 
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Eizirik, 1994 )  which result increased quantity of insulin is released into the 
circulation (Dunn and McLetchie, 1943 ). The cells of the islands of 
Langerhans become necrosed, being exhausted from overwork, leading to 
the symptoms of diabetes mellitus (Dunn and McLetchie, 1943). 
Glucose tolerance test carried out in this experiment showed that, the oral 
administration of C.verum to diabetic rats lowered significantly the plasma 
glucose level of diabetic rats ( Group D Vs Group C ) when measured at 
0,1,2 hour after fasting ,this indicated that C.verum administration has 
significants effect on plasma glucose in diabetic rats. However , the oral 
administrated of C.verum did not lower the plasma glucose level to normal 
concentration when diabetic rats administrated orally with C.verum powder  
(Group D ) were compared to normal rats administration orally with 
C.verum (Group B ) or normal control rats (Group A ). These results are 
similar to those of Khan etal. (2003) investigation that revealed cinnamon 
powder reduced blood glucose of type 2 diabetic patient which was 
significantly lower only in the group receiving 6g of cinnamon after 20 days. 
Also the results of this study are similar to those of Abass (2008) who found 
that the oral administration of C. verum reduced significantly serum glucose 
level of normoglycemic fasting rats and hyperglycemic rats when compared 
to control groups. The results of this experiment are also in line with Mang 
etal. ( 2007 ) who reported moderate glucose lowering effect of aqueous 
cinnamon extract on fasting plasma glucose when compared to control group 
of type 2 diabetes (10.3% Vs 3.37% ) . However, the hypoglycemic effect 
observed in the present research and previons ones (Khan etal., 2003 Mang 
etal., 2007 ) was not noticed by Ziegenfuss etal .(2006) and Roussel etal. 
(2006), they reported no effects on blood glucose were found after a 6 weeks 
intervention of supplementation with an aqueous cinnamon extract (500 
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mg/d), but they reported  effect after 12 weeks. Similarly, no beneficial 
effects were found in post menopausal women with type 2 diabetes after 
only 6 weeks (Vanschoonbeek, 2006). 
In 2001 a study by researchers at the USDA`s Human Nutrition 
Research Center showed that bioactive compounds in Cinnamon trigger an 
insulin-like response in fat cells (Jarvill et al., 2001). These compounds 
stimulate glucose uptake into cell and increased glycogen synthesis via the 
activation of the enzyme glycogen synthase.  
The bioactive compounds in cinnamon appear to potentiate insulin activity 
at the level of the cell receptor for insulin. It has been shown that insulin 
resistance involves down regulation of insulin signaling characterized by de- 
phosphorylation of the receptor (Nadiv et al., 1998). Enzymes called protein 
tyrosine phospho kinases (PTPases) are believed to decrease receptor 
phosphorylation, and increase PTPases activity has been observed in insulin 
resistant rats (Begum et al., 1991). Cinnamon compound have demonstrated 
the in vitro ability to inhibit PTP-1 and increase autophosphorylation of the 
insulin receptors (Impal-Radoserich et al., 1998). In recent animal study, the 
cinnamon (cassia) extract was administered to rats for three weeks. 
Following this, the rats were infused with insulin and glucose to assess their 
insulin response, increased phosphorylation of the insulin receptors was 
observed in skeletal muscles of these rats, suggesting that cinnamon has the 
ability to potentiate insulin function by normalizing insulin signaling, 
leading to improve uptake of glucose into skeletal muscle (Qin et al., 2003). 
Thus the observed hypoglycemic of C.verum in this study may be attributed 
to its bioactive compounds in cinnamon that appear to potentiate insulin 
activity at the level of the cell receptor for insulin. 
Jarvizll-Taylor etal. (2001) established that the active component in 
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cinnamon responsible for its insulin – like activity is water –soluble 
chemical compound called methyl hydroxychalcone polymer (MHCP). 
They found that MHCP was highly effective, providing essentially the same 
biological activity as insulin itself. It was effective not only in increasing the 
uptake of glucose by cells , also of stimulating the synthesis of glycogen , a 
polymeric form of glucose that is stored primarily in the liver and muscle 
tissues for use at times of peak energy demand , such as exercise. MHCP 
makes cells more responsive to insulin, i.e., it increases insulin sensitivity, 
the opposite of insulin resistance. The C.verum used in the present 
experiments was not an extract of C.verum bark but rather whole powdered 
bark which of course contains MHCP along with every other compound of 
the bark, water soluble or not, thus the observed hypoglycemic of C.verum 
in this study may be attributed to its MHCP content. 
  The USDA has now determined that the bioactive compounds in cinnamon 
are water- soluble procyanidin type-A polymers of catechins and 
epicatechin. In a 2004 study, type-A polymers were isolated from cinnamon 
and characterized by nuclear magnetic resonance and mass spectroscopy. 
Type-A polymers were found to increase in vitro insulin activity by a factor 
of 20. Type-A polymers also exhibited antioxidation activity, as measured 
by inhibition of free radical production in platelets, these results suggest that, 
in addition to regulating glucose metabolism, cinnamon may help protect 
cell membrane by controlling the lipid peroxidation associated with 
disruption in insulin function (Anderson et al., 2004). Khan et al. (1990) 
isolated an unidentified factor from cinnamon and termed this factor as 
insulin potentiating factor (IPF). They demonstrated that IPF increased the 
activity of insulin three fold in glucose metabolism in rat epididymal fat 
cells. 
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Antioxidants are essential to human body to neutralize free- reactive oxygen 
radical, to maintain functional cellular membrane and structure .Furthermore 
free radicals associated with impaired glucose metabolism and antioxidant 
have been implicated in regression of diabetes mellitus. Cinnamon contains 
oligomeric proanthocyanidins (OPC) which has antioxidative effect (Gu et 
al., 2003). The observed hypoglycemic effect of C.verum in this study may 
also attributed to its content of   OPC. 
Some scientists had been concerned about potentially toxic effects of 
regularly consuming Cinnamon. New research showed that the potentially 
toxic compounds in cinnamon bark are found primarily in the lipid soluble 
fractions and are present only at very low levels in water soluble cinnamon 
extracts, which are the ones with the insulin – enhancing compounds. 
Cinnamon does not contain a measurable amount of goitrogen, oxalate or 
purine and is not known to cause food allergies (WHO, 2007). 
The oral administration of C.verum decreased significantly plasma total 
protein concentration in normal and diabetic rats in this study .This revealed 
the cinnamon has slight effect on liver or kidney, since it was reported that 
drastic alteration in plasma protein values may be observed in association 
with both kidney and liver diseases (Coles, 1986). The oral administration of 
C.verum had no effect on plasma albumin concentration in normal or 
diabetic rats. However ,the albumin concentration in diabetic rats 
administrated orally with C. verum  (Group D) and diabetic rats (Group C) 
was numerically  low when compared with normal control rats (Group A) 
.This hypoalbumin may be attributed to diabetes ,as it is known 
hypoalbumin develop as result of excessive protein breakdown which occurs 
in prolonged fever, and uncontrolled diabetes mellitus (Coles, 1986). The 
oral administration of C.verum  had significant affect on plasma AST in both 
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normal and diabetic rats in this experimental , the administration of C.verum 
increased significantly the plasma AST level in normal rats administrated 
orally with C.verum(Group B) and increased numerically in diabetic rats 
administrated orally with C. verum(Group D).This increase in AST might 
indicate slight pathological changes in the liver as AST increased in serum 
when cellular degeneration or destruction in the liver occurs (Coles,1986) 
.Also in this experiment there was no significant different in plasma ALT 
between normal and diabetic rats this disagree with Mannipieri et al .,(2005) 
who reported that higher ALT was significantly associated with both 
impaired glucose tolerance and diabetes .The plasma bilrubin level was not 
significantly different in normal and diabetic rats ,however  the bilrubin 
level in diabetic rats was numerically lower than normal control rats and 
diabetic rats orally administrated with C. verum .This reduction in bilrubin 
agree with that of Stone et al . (1997) who reported significant increase in 
bile acid excretion and bile flow in streptozotocin induced diabetic rats and 
decrease in plasma bilrubin concentration .This explain by the fact that ,the 
bilrubin increase is due to decreased removal of bilrubin by hepatocellular 
transport (Coles ,1986) . 
In this experiment, the oral administration of C. verum had significant effect 
in plasma triglyceride level in normal and diabetic rats, the plasma 
triglyceride level in the diabetic rats administrated orally with C.verum 
(Group D) was numerically higher than diabetic rats (Group C) .This 
disagree with finding of Khan et al. (2003) who reported high triglyceride 
level which was reduced by consumption of cinnamon by human patient 
with type2 diabetes.  
It was also noticed in the current experiment, the level of plasma cholestrol 
was significantly lower in diabetic rats administrated orally with C.verum 
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(GroupD) when compared with the diabetic rats (Group C) .This agree with 
Khan et al. (2003) who reported that high cholestrol level which was 
reduced by consumption of cinnamon by people with type2 diabetes. 
The level of LDL-c in diabetic rats was not affected significantly by oral 
administration of C. verum, but decreased   numerically in diabetic rats 
administrated orally with C.verum (Group D) when compared to diabetic 
rats (Group C) .This agree with findings of Khan etal. (2003) who reported 
non significant difference in level of LDL-c in people with type2 diabetes 
after consumption of cinnamon after 20 days. This experiment also showed 
there was non significant difference in plasma HDL-c in diabetic rats 
administrated orally with C.verum (GroupD) when compared to the diabetic 
rats (Group C). This agrees with khan etal. (2003) who reported non 
significant difference in the level of HDL-c in people with type2 diabetes 
after consumption of cinnamon. Concluded that Khan et al. (2003) 
cinnamon reduced the serum glucose, total cholestrol and LDL-c in people 
with type2 diabetes. The administration of C.verum in this study had no 
significant effect on the body weight of diabetic rats and normal rats. Also it 
was observed in this study, the body weight of diabetic rats was non 
significantly lower (5%) than the body weight of normal rats. This agrees 
with finding of Fath Elrahman (2006). Who reported significant decrease in 
the body weight of diabetic rats. The reduction in the body weight of 
diabetic rats confirms the previous work of Greene and Lattimer. (1993) 
which showed experimental diabetes significantly lowered the final body 
weight by about 48%. Weight loss is clinical sign associated with diabetes 
(Coles, 1986) .Hence it could be conclude cinnamon is promising 
antidiabetic agent and can be used to improve glucose and insulin 
metabolism.        
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CONCLUSIONS AND RECOMMENDATIONS 
CONCLUSIONS  
 
From observations and results of this investigation, it can be concluded that: 
 
 1- C.verum bark powder increased significantly plasma glucose uptake in   
     alloxan induced diabetic rats.  
2-  C.verum bark powder had no significant effect on plasma albumin, 
     bilirubin, ALT and LDL-c  concentration in alloxan induced diabetic rats 
     and normal rats. 
3-  C.verum bark powder decreased significantly plasma total protein,  
     cholestrol and HDL-c in alloxan induced diabetic rats and normal rats. 
4-  C.verum bark powder increased numerically plasma AST in alloxan  
     induced diabetic rats and increase significantly in normal rats. 
5-  C.verum bark powder decreased numerically plasma triglyceride in 
     alloxan induced diabetic rats and normal rats. 
6-  Therefore,   C.verum could be considered a promising  antidiabetic agent   
     which can be used to reduce blood glucose.   
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RECOMMENDATIONS 
 
     Since Cinnamomum verum is promising antidiabetic agent it is 
recommended that: 
1-        The active ingredient in C.verum should be identified. 
2-        Future research should be carried out to determine the mechanism of 
           action of each fraction on blood glucose level. 
3-       The proper dosage and potential interaction with other medicinal 
           Plants and synthetic drugs, has to be studied. 
4-        The safety of C.verum should be examined by administering very 
           high dose for long period of time.  
                      
   
  
 58
REFERENCES  
Abass, F.D.  (2008).   The     hypoglycemic   effect of Cinnamomum verum 
        (ELGERAFA) in RATS. M.Sc. Thesis, U of.K.Sudan.    
Alice Hart  , D  .   (2007).  Chillies  are    the spice    of   life   ,  cited  by 
        Encyclopaedia Britannica .(2008) .Cinnamon.11 edition. 
American   Diabetes  Association , (2007)    . Diagnosis  and classification of  
           diabetes mellitus (position statement)  . Diabetes Care , 30: S42-S47. 
Anderson,R.,Broadhurst,C.L.,Polansky, M.M.,Polansky,W.F., Schmidt, 
          A.,Khan,N.W., Schone,D. and Graves ,D.J.(2004) .Isolation and 
         characterization of  polyphenols type A  polmers   from  Cinnamon  
          with insulin like biological activity .Agric. Food Chem.,52(1)65-70. 
Anderson , R.,Broadhurst ,C.L .,Polansky , M.M .,Polansky,W.F., Schmidt, 
          A.,Khan,N.W., Schone,D. and Graves ,D.J. (2001). Isolation  and  
          Characterization of chalcone polmers from  cinnamon with   insulin  
          Like biological activities .J.Amer col . Nutr., 17:1-504. 
Asima, C. and Pakrashi, S.C. (1995).The treatise on Indian medicinal    
          plants.Vol.4. Pp 325. 
Assmann,   G.,  Jobes,  H.U., Nolte, W., and   Schrierer,  H. (1984).  LDL. 
           Cholestrol determination in blood serum  following   precipitation of  
           LDL with polyvinyl sulfate. Clin. Chem. Acta., 140:77-83.  
Beak ,   L.   (2006).   Cinnamon,     Feature  Food. 
        http://www. leslebeck.com /ingredient _index. Php?featured_  
        Food= 80>.  
Beers, M. H. and Berkow, R.S.  (2006)  . Infectious diseases :  The Merck  
          Manual for Healthcare Professional's . Whitehouse Station  ,   NJ:  
          Merck & CO., Inc  
Begum , N.,Sussman , K.E. and Draznin, B. (1991).Differential effects of  
 59
            diabetes  on    adipocytes      and     liver     phosphotyrosine   and  
            phosphoserine phosphatase  activities .Diabetes ., 40 (12): 1620- 1629. 
Bennett, P.and Brown.M.J.(2003). Clinical pharmacology .9th edition ,Elsever 
            limited. p 679-699. 
Boon, N.A., College, N., Walker, B. and Huater, J. (2006).Davidson,s 
         Medicine.  20th  edition, Elsever  limited ., p 806-843. 
Broadhurst , C.L.,Polansky ,M.M. and  Anderson , R.A. (2000).  Insulin - like  
           biological activity of culinary  and  medicinal plant aqueous extracts in  
           vitro. J. Agric. Food Chem ., 48(3) : 849- 852. 
,, Cassia ,, Wikipedia, The free   Encyclopedia .15 Jan 2007, 22:34.UTC. 
        Wikipedia   Foundation   , Inc  .  18  Jan   2008      Available    at  :  
       <http://en.wikipedia.org/w/index.php?title=Cassia&oldid=1009 
       68318>.Accesed March 5, 2007. 
Coa, H.,  Polansky, M.M and Anderson, R.A. (2007).  Cinnamon extract and 
           polyphenols affect the expression of   tristetraprolin, insulin receptor,  
          and  glucose  transporter  4 in  mouse   3T3 – LJ  adipocytes .  Arch, 
          Biochem, Biophys., 459:214-222. 
Coles, E.H. (1986) .Veterinary clinical pathology . 4th edition . Pub . W.B. 
          Saunder Company  U.S.A. Pp 615. 
Dandona, P., Aljada, A .,Chaudhuri, A.and Bandyopadhyay, A .  (2003) The 
        potential   influence  of inflammation     and insulin  resistance  on  the  
        pathogenesis and treatment of atherosclerosis - related  complications 
        in type 2  diabetes. J. Clin. Endocrinol. Metab., 88:2422-2429. 
Duke ,   J.A., Beckstrom -  Stemberg, S. and   Broadhurst, C. L   .  ( 1998).  
              Phytochemical and  ethnobotanical data  base , U. S.Department  
              of Agriculture. http:// www .ars- grin. Gov/ ~ngrisb/. 
 60
Dunn, J.   S.  and      McLetchie , N.  G. B.  (1943) . Lancet ii,         384-387. 
Eizirik, D., Pipeleers, D., Ling, Z.,Welsh, N.,Hellerström ,C.and Andersson, 
A. (1994).Major species differences between humans and rodents  
B. in the susceptibility to pancreatic beta-cell      injury. Proc Natl 
C.  Acad Sci U S A.,  91 (20): 9253–9256.  
El-Dokhakhny, M., Barakat, M., Abd El- Halim , M. and Aly, S . M . (2000). 
          Effect of Nigella sativa oil on gastric secretion and ethanol  -  induced  
          ulcer in rats . J . Ethnopharmacology .,72: 299 – 304.  
Elgazali, E.B., Gamal Khalid, S.H., Eltohami, S.M., Abdullah, S., Wail ,L.  
            and Yagi, M. (1998). Common  medicinal  plant in Khartoum state.       
            National Center for Research (MAPRI) Khartoum .Sudan (in Arabic). 
Fath Elrahman,  M.A. (2006). The hypoglycemic and anti-diabetic effects  
        of Pimpinella anisum .M.Sc. Thesis, U of.K.Sudan. 
Felter,   H.     (2007)  .     Cinnamomum –    Cinnamon . 
            http://www.henriettsherbal.com/eclectic/Kings/cinnamon.htm>. 
Forbes, C.and    Jakson, W. (2003). Clinical Medicine .3 th   edition,  Elsever 
        limited. p 314-326.  
Fowler, M.J. (2007). Diabetes: magnitude and mechanism .Clinical Diabetes , 
        25: 25-28. 
Gilman, G.A., Niles, S.A. and Taylor, P. (1992).Pharmacological basis of 
       therapeutics .Vol.11.Eighth edition .Mc Graw-Hill International edition  
       medical series. 
George,  M.   (2007). Foundation , Cinnamon  ground. Research: Thalido 
       http://www.whfoods.com/genpage.php?tname=foodspice&dbid=68. 
Greene , D .A and Lattimer , S .A . (1993) . Impaired rat sciatic nerve sodium 
            potassium adenosine triphosphate acute streptozocin diabetes and its 
            correction by dietary myo-inosital .Clin.Invest.,72 (3) : 1058 -1063. 
 61
GU,  L.,  Kelm,  M. A. and Hammerstone, J. F. (2003).   Screening of foods  
       containing proanthocyanidins and their structural characterization using  
      LC-MS/MS and thiolytic degradation .J.Agri.Food Chem., 51:7513-7321. 
Hlebowicz, J., Darwiche , G., Bjorgell , O and Almer , L.O . (2007). Effect of  
            cinnamon on  postprandial  blood  glucose , gastric   emptying ,   and  
            satiety  in   healthy subjects . Am J Clin Nutr .,85 (6):1552 – 1556.  
Imparl – Radosevich, J.,Deas , S.,Polansky, M.M.,Baedke , D.A.,Ingebritsen, 
             T.S., Anderson,  R.A. and Graves , D.J. (1998) .Regulation of PTP-1 
             and insulin receptor kinase by fractions from cinnamon: implication 
             for cinnamon regulation of insulin signaling .Horm. Res., 50:177-182.                   
Jarvill-Taylor,    K.J.,    Anderson,   R .A.      and Graves,     D.J. (2001).  A 
           hydroxychalcone derived from cinnamon function as a mimetic for 
           insulin in 3T3-L1 adipocytes. J Am. Coll Nutr., 4:327-336.           
Johnston , C.F.,Shaw , C., OHare , M .M. and Buchanan ,K  . D. (1988). 
            Chromogranin A and its derived  peptides   in the rats    and  porcine 
            gastro- entro pancreatic system In: Clinical Diabetes - An illustrated  
            Text   ( Besser , BBodansky and Cudworth , eds ) .  Gower Medical  
             Publishing , London , England .1 .1 . 
Jorpes , T. A . (1949). High purified insulin. Arch. Intern .Med.,83: 363 - 371. 
Kasper, D.,Braunwald, E., Anthonys, F., Hauser, S., Longo, D .and Jameson, 
             J.   (2005) . Harrison,s   principles  of internal medicine . 16 th edition,  
            McGraw-Hill companies, p 2152-2183. 
Khalil, A . B . (2004). Annual   workshop   on    Diabetes   Mellitus  and  its  
             Complications  Al Ain, United  Arab  Emirates, Int . J .Diabetes and  
             Metabolism .,12: 19-23. 
Khan, A., Safdar, S., Muzaffar , M., Khttak, K.N. and Anderson,R.A . (2003).              
 62
            Cinnamon improves glucose and  lipids of people with type2 diabetes.  
            Diabetes Care , 26  (12).  3215- 3218. 
Khan, A.,Bryden, N.A., Polansky, M.M. and Anderson, R.A. (1990).  Insulin  
   potentiating factor and chromium   content  of  selected  foods and  
   spices . Biol. Trace Elem. Res .,24: 183- 188. 
Kim ,C.,Newton, K.M.and   Knopp, R.H. (2002).Gestational diabetes and the  
             incidence of type2 diabetes. Diabetes Care ,25: 1862 – 1868. 
Knowler, W.C., Barrett- Connor, E.,Fowler, S.E.,Hamman, F.R., Lachin, J.M.   
            Walker. E  .A. and   Nathan, D  .M. (2002) .  The diabetes prevention 
            program    research  group  : Reduction   in   the   incidence of  type2  
           diabetes   with   lifestyle   intervention or  metformin . N. Engl. J Med., 
           346: 393- 403. 
Kumar, P and Clark, M.   (2002). Clinical medicine .Fifth edition, Bath press 
         limited ., p 395-397.  
Kumar,P and Clark, M.(1998).Clinical medicine. Fourth edition, Harcourt,  
         Brace  and company limited., p 244-959. 
Lee, S. H. and Lee, S.Y. (2005). Inhibition effect of 2-hydroxycinamaldehyde  
       on nitric oxide production through inhibition of NF-kappa B activation in    
              RAW 264.7 cells. Biochem .Pharmacol ., 69:791-799. 
Leibowtz,G.,Tsur, A.,Chayen, S.D.,Salameh, M.,Raz, I.,Cerasi, E.and Gross, 
           D. (1996). Pre- clinical Cushing,s  syndrome : an unexpected frequent 
           cause   of  poor  glycaemic  control in  obese  diabetes  patient . Clin. 
           Endocrinol .,44: 717- 722.  
Lewis, E.J., Hunsicker, L. G., Bain, R.P. and Rohde, R.P.(1993). The effect of    
         angiontensin- converting – enzyme inhibition  on diabetic nephropathy    
         new England,Journal of Medicine , 329(20):1456-1462. 
 63
Linn, T.,Ortac, K.,Laube  , H. and  Federlin, K. (1996) . Intensive therapy in 
             adult  insulin  – dependent  diabetes mellituse   is  association  with  
              improved insulin sensitivity and reserve: a randomized ,  controlled  
              prospective    study   over 5   years   in  newly diagnosed  patients.  
              Metabolism ,45: 1508 - 1513. 
Lopez, P., Sanchez, C., Batlle, R. and Nerin, C. (2005). Solid and vapor-  
            phase  antimicrobial activities of six essential oils : susceptibility  
            of selected foodborne bacterial and fungal strains .J. Agric.Food         
            Chem., 53(17):6939- 9646. 
MacSween, R.and  Whaly,  K. (1992). Muir,s   Textbook of pathology.30th 
           edition , Oxford University prees, Inc. NewYork., p 791-793. 
Mancini-filho, J.,Van-Koiij, A., Mancini, D.A., Cozzolino, F.F., Torres, R.P.  
       (1998). Antioxidant activity of cinnamon   (Cinnamomum zeylanicum, 
       Breyne) extracts. Boll Chim Farm., 137(11): 443-447. 
Mang, B., Wolters, M., Schmitt, B .,Kelb, K., Lichtinghagen, R., Stichtenoth, 
         D.O . and   Hahn, A. (2006) . Effects of a cinnamon extract on plasma  
         glucose, HbA1c   and serum lipids in diabetes mellitus type 2. Eur J Clin  
         Invest., 36: 340-   344. 
Mannipieri , M .(2005).  Metabolic syndrome / Insulin resistance syndrome/ 
             Pre. Diabetes Care, 28: 1757 – 1762 . 
Marles, R.J.and Franthworth, N.R.(1994). Plants as sources of antidiabetic  
              agents. Econ. Med. Plant. Res., 6: 149- 187. 
Murray, R., Granner,D., Mayes, P.and Rodwell, V.(2000).Harper,s 
     Biochemistry .25th  edition , Appleton and Lange ., p 610-622. 
Nadiv ,O.,Shinitzky, M., Manu, H., Hecht, D., Roberts, C.T., LeRoith, D. and  
            Zick, Y  .(1998) .Elevated  protein    tyrosine phosphatase activity and 
 64
       increased membrane viscosity are association with impaired activation 
       of  the     insulin    receptor  kinase in   old   rats. Biochem. J., 298(2):  
      443-450. 
Nir. Y., Potasman, I.and Stermer, E. (2000). Controlled trial of the effect 
     of cinnamon extract on Helicobacter pylori. Helicobacter, 5: 94-97.      
Noor, H. and Aschroft, S. J. (1989) Anti – diabetic effects of Tinospora  
            crispa in rats. Journal of Ethnopharmacology, 27 (1-2) :149-161. 
Ooi, L.S., Li,Y. and Kam, S.L.(2006). Antimicrobial activities of cinnamon  
          oil  and  cinnamaldehyde     from the      Chinese      medicinal   herb                               
                  Cinnamomum   cassia Blume . Am  J.Chin Med.,   34: 511-522.   
Pawar ,V.C.and Thaker ,V.S.(2006).In vitro efficacy of 75 essential oils  
            against Aspergillus niger. Mycoses, 49: 316-323.  
Qin ,B., Nagasaki, M., Bajotto ,G., Oshida, Y. and Sato,Y. (2003).Cinnamon 
           extract (traditional herb)  potentiate in vivo insulin – regulated glucose  
           utilization via enhancing insulin signaling in rats.  Diabetes Res.  Clin . 
           Pract., 62:139-148.   
Remmers, P.(1994). Bipliography .Libelle.,6:45-47. 
Richmond ,W.(1973).Preparation and properties of a cholestrol oxidase from  
         Nocordia  sp . and  its  application  to the  enzymatic  assay  of total 
         cholestrol in serum . Clin .Chem ., 19: 1350 – 1356. 
Rodriguez   , C  . J    . , Loyola   ,   J . and   Schmeda   ,  H . G .    ( 1992 ). 
            Hypoglycemic   activity   of   Hexachlamys  edulis  extract  in  rats . 
            Phytotherapy Resarch , 6 : (1) 47 – 49 
Roussel,  A.M.,  Hininger  ,I., Ziegenfuss,  T.N.  and Anderson,   R.A.(2006). 
           Cinnamon improves the antioxidant variables of people  with  impaired   
           fasting   glucose . J.Am.Coll. Nutr., 25:1-443. 
Sanchez – de - medina , F ., Gamez , M.J., Jimenz . I ., Jimenz . J., Osuna , L.  
 65
            I . and Zarzuelo , A .(1994) . hypoglycemic activity of Juniper berries.  
            Planta   Medicage , 60 : (3 ) 197 – 200.  
Schlichtkrull , J., Brange, J., Ege, H., Hallund , O., Heding , L.G ., Jorgensen, 
           K.H., Markussen, J., Stahnke, P., Sundby,F . and Voloud, A .(1970). 
           Monocomponant insulin and its clinical implication . Diabetologia ,6: 
           80 – 81. 
Scott, D. A . (1934) . Effect of zinc deficiency in rats on insulin release   
              from Pancreas. Biochem. J., 28: 1592 – 1602.  
Shan, B., Cai, Y.Z ., Sun, M .and Corke ,H.(2005). Antioxdiant capacity 
            of  26   spice   extracts   and characterization   of  their phenolic  
            constituents ,, . J.Agric.Food Chem.,53(20):7749-7759. 
Srinivas , P . and    Patil . P.A .( 1993 ) . Hypoglycemic activity of    Brassica  
            oleracia var. gongloides in normal and diabetic rats. Fitoterapia , 
             64 (4): 301-303.  
Steiner , D.F. (1977) .The banting memorial lecture insulin  today . Diabetes , 
           26: 322 – 340.  
Stone, J.L.,Braunsterin, J. B., Beaty, T. M ., Sanders, R.A. and  Watkins, J.B. 
           (1997)  .  Hepatobiliary  excretion  of  bile  acids and Rose Bengal in 
           streptozotocin induced and genetic diabetic rats . Pharmacology,281 
          (1) :412 – 419 . 
Szkudelski, T. (2001).The   mechanism of alloxan   and streptozocin action 
         in B    cells of the rat  pancreas. Physiol. Res.,50(6):537-546. 
Taher,M   .,     Majid, F. and    Samidi, M. (2008).    Aproanthocyandin from       
        Cinnnamomum Zeylancium stimulates phosphorylation of insulin  
        receptor in 3T3- LI  adibocyties. Journal Teknolog ., 44(F):53-68.  
Takenaga ,M., Hirai ,A., Terano , T.and Tamura, Y .(1987).In vitro effect  of   
              cinnamic  aldehyde ,  a main  component  of   cinnamomi  cortex ,      
 66
             H. J.Pharmacobiodyn .,10 (5) :201 – 8.  
The         Encyclopaedia     Britannica   . (2008)  .    Cinnamon .    11edition. 
            http://www.britannica.com/EBchecked/topic/118117/cinnamon.  
The World ,s Healthiest Foods .  WH Foods .   (2007) Cinnamon  , ground . 
            http://www. whfoods.com /genpage.php?tname = foodspice  & 
            dbid =68. 
Thomas ,G .and Ramwell, P.W. (2004) . Nitric oxide, donors  and   inhibition. 
              In: Basic and Clinical Pharmacology 9th ed.  Katzung BG, ed. New 
              York, NY: McGraw –Hill Companies, Inc. 
Trinder, P. (1969). Determination of blood glucose using 4-aminophenazone. 
             J. Clin. Path. 222461. 
Tyrberg  , B.,  Andersson , A. and  Borg , L. (2001).  Species  differences in 
              Susceptibility   of   transplanted and cultured pancreatic islets to the  
              beta-cell toxin alloxan. Gen Comp Endocrinol ., 122 (3): 238–51. 
Vanshoonbeek,  K., Thomassen, B.J., Senden, J.M.,   Wodzig, W.K. and Van- 
           Loon,  L.J. (2006) . Cinnamons supplementation does not   improve 
          glycemic control in postmenopausal type2 diabetes  patients.J , Nutr., 
          136(4):977-980. 
Villon , C. and Chaumont , J.P. (1994). Antifungal properties of essential oils 
            and their main component upon Cryptococcus neoforma. Mycopatho-  
            logia , 128: 151-153 . 
Ziegenfuss, T.N.,Hofheins, J.E., Mendel , R.W., Landis ,J. and Anderson , R.  
             (2006).  Effect  of  a water –  soluble   cinnamon  extract  on   body  
             composition and features of the metabolic syndrome in pre- diabetic  
             men and women . J. Int .Soc.Sports Nutr., 3: 45-53. 
 
